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ABSTRACT
Extracellular Matrix from Whole Porcine Heart Decellularization for
Cardiac Tissue Engineering
Nima Momtahan
Department of Chemical Engineering, BYU
Doctor of Philosophy
Heart failure is one of the leading causes of death in the United States. Every year in the
United States, more than 800,000 people are diagnosed with heart failure and more than 375,000
people die from heart disease. Current therapies such as heart transplants and bioartificial hearts
are helpful, but not optimal. Decellularization of porcine whole hearts followed by
recellularization with patient-specific human cells may provide the ultimate solution for patients
with heart failure. Great progress has been made in the development of efficient processes for
decellularization, and the design of automated bioreactors. In this study, the decellularization of
porcine hearts was accomplished in 24 h with only 6 h of sodium dodecyl sulfate (SDS) exposure
and 98% DNA removal. Automatically controlling the pressure during decellularization reduced
the detergent exposure time while still completely removing immunogenic cell debris.
Stimulation of macrophages was greatly reduced when comparing native tissue samples to the
processed ECM. Complete cell removal was confirmed by analysis of DNA content. General
collagen and elastin preservation was demonstrated by SEM and histology. The compression
elastic modulus of the ECM after decellularization was lower than native at low strains but there
was no significant difference at high strains. Polyurethane casts of the vasculature of native and
decellularized hearts demonstrated that the microvasculature network was preserved after
decellularization. A static blood thrombosis assay using bovine blood was also developed. A
perfusion bioreactor was designed and right ventricle of the decellularized hearts were
recellularized with human endothelial cells and cardiac fibroblasts. An effective, reliable, and
relatively inexpensive assay based on human blood hemolysis was developed for determining the
remaining cytotoxicity of the cECM and the results were consistent with a standard live/dead
assay using MS1 endothelial cells incubated with the cECM. Samples from the left ventricle of
the hearts were prepared with 300 µm thickness, mounted on 10 mm round glass coverslips.
Human induced pluripotent stem cells were differentiated into cardiomyocytes (CMs) and 4 days
after differentiation, cardiac progenitors were seeded onto the decellularized cardiac slices. After
10 days, the tissues started to beat spontaneously. Immunofluorescence images showed confluent
coverage of CMs on the decellularized slices and the effect of the scaffold was evident in the
arrangement of the CMs in the direction of fibers. This study demonstrated the biocompatibility
of decellularized porcine hearts with human CMs and the potential of these scaffolds for cardiac
tissue engineering. Further studies can be directed toward 3D perfusion recellularization of the
hearts and improving repopulation of the scaffolds with various cell types as well as adding
mechanical and electrical stimulations to obtain more mature CMs.
Keywords: heart, acellular biological matrices, extracellular matrix, automation,
cardiomyocytes, induced pluripotent stem cells, differentiation, decellularization,
recellularization
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1

LITERATURE REVIEW
Every year more than 600,000 people die of heart disease in the United States and that is

1 in every 4 deaths. Although the annual number of victims varies in different states (Figure 1-1),
heart failure is the number one cause of death in the United States.

Figure 1-1. Heart disease death rates in adults more than 35 years of age 2007-2009 [1].
End stage heart disease is most commonly associated with severe coronary artery disease
(CAD), cardiomyopathy, and cardiac conduction problems causing an irregular heart rhythm that
creates a high risk of causing sudden cardiac death. For patients with end stage heart disease the
only option is to receive a heart transplant; however, the demand for heart transplants is higher
than the supply of suitable hearts. Artificial hearts also have not been able to provide an
appropriate solution because of the risk for adverse immune response even with daily
immunosuppression medications, and inherent thrombogenicity and blood incompatibility
1

problems that increase the risk of stroke and hemolytic anemia in patients receiving these hearts.
Tissue engineered hearts that are created by decellularization followed by recellularization with
the patient’s own cells exhibit promising advantages while creating an unlimited source of donor
hearts. Also tissue engineered hearts are not immunogenic, meaning they will not be rejected by
the recipient’s body because the natural scaffold is not immunogenic, and the cells are sourced
from the same patient. Advances in research with stem cells, such as the discovery of IPS
(induced pluripotent stem) cells have increased the hope to be able to create the ideal tissue
engineered heart.
Whole heart recellularization has been accomplished with rat hearts and spontaneous
beating of the CMs has been reported [2, 3]. However, the function of these tissue engineered
hearts is not appropriate to sustain life and other issues such as thrombosis and immunogenicity
are not completely resolved.
If DNA and some membrane proteins from the cells enter the body, it will initiate an
immune response; therefore, decellularization is an important step in creating tissue engineered
hearts. Ideal decellularization can be achieved by completely removing all cells and cell debris
from the heart, while keeping the heart scaffold’s vasculature intact and also preserving the
important growth factors, glycosaminoglycans (GAGs) and proteins in the extracellular matrix
(ECM).
Toward making tissue engineered hearts beneficial for humans, the function of these
hearts must be improved and the approach used for rat hearts should be scaled up to human size
hearts. Porcine hearts are similar to human hearts in terms of size and anatomy, thus they are
useful for this research.
2

The use of decellularized porcine whole organ scaffolds combined with autologous
human patient-specific cells would provide an essentially unlimited supply of organs for
transplant. Great progress has been made in culturing patient-specific human cells (e.g., induced
pluripotent stem cells [iPSC]) and the promise of constructing a whole human organ from
autologous human cells and decellularized porcine organ scaffolds is getting closer to reality [4].
The two steps in this process are decellularization of porcine organs while preserving the
extracellular matrix (ECM) and recellularization with a human patient’s cells. In order to fully
develop this technology, there is a need to optimize decellularization processes and equipment to
reliably and safely produce acellular hearts in large quantities for combination with human cells
[5]. The processes for recellularization and pre-conditioning the organs in bioreactors prior to
implantation also must be optimized. Finally, the organs must be characterized to make sure they
are safe and meet all performance requirements.
One of the critical requirements for effective performance of recellularized bloodcontacting scaffolds is the prevention of thrombosis. Thrombosis leads to the disruption or
blockage of intravascular blood flow and is a consequence of uncontrolled clotting (the
formation of fibrin networks) and activation of platelets due to flow disturbances and surface
chemistry. The process of thrombus formation includes adhesion of platelets to surfaces, platelet
aggregation, and the combination of platelets with fibrin and other cellular components. Thrombi
that are released from a surface become thromboemboli, which may lodge in downstream blood
vessels and interrupt blood flow to an area of tissue such as the brain, creating a stroke as cells in
the brain begin to die. If anticoagulants, antithrombotics, fibrinolytics, and thrombolytics (e.g.,
coumarins, heparin), or antiplatelet agents (e.g., aspirin) are used during the implantation of
recellularized organs to prevent clotting, this may result in uncontrollable hemorrhage.
3

Developing a reliable method for ameliorating the thrombogenicity of recellularized organs prior
to implantation would be a major advance for this technology.
In reviewing the literature, numerous articles exist on the decellularization and
recellularization of whole organs. These include eleven review papers on hearts, kidneys,
pancreas, lungs, livers and other organs [4-14] totaling 880 citations. Of these citations, 13
papers were identified as most relevant to the design of an automated system for decellularizing
whole hearts [2, 3, 15-25]. The types of detergents, concentrations of solutions, flow rates,
pressures, incubation temperatures, total number of steps, and organ exposure times were
identified as major factors for consideration. These parameters are summarized in Table 1-1.
Based on these recommendations, an optimized porcine heart decellularization protocol was
conducted with excellent results [26]. Additional papers from the review of the literature
identified the best techniques to introduce cells back into the decellularized hearts, growth and
differentiation factors required to control cell phenotypes, bioreactor designs, and evaluation
methods that have been developed.
The overall purpose of this review chapter is to evaluate and highlight optimal strategies
for decellularization, recellularization, growth factor delivery, bioreactor design, evaluation of
whole organs, and prevention of thrombosis of blood-contacting porcine whole organ scaffolds.
Reviewed papers on decellularization (Table 1.1) were supplemented with articles on cells
available for recellularization (Table 1.2), growth factor delivery (Table 1.3), bioreactor design
(Table 1.4), evaluation of tissue engineered organs (Table 1.5), and preventing thrombosis
(Table 1.6).

4

1.1

DECELLULARIZATION

The process of decellularization begins with harvesting a heart from a heparinized animal
under general anesthesia or from an animal at an abattoir immediately after exsanguination. For
the latter, heparinized physiologic saline is used for antegrade coronary arterial perfusion and
endothelial lavage to remove blood from the cardiac chambers. Heparinized salt solutions are
typically used to remove circulating blood from the heart and to prevent coagulation in the
smaller vessels. The heart may be transported at room temperature or on ice, and stored in the
refrigerator or freezer for up to a year. Once initiated, the decellularization process is generally
continuous, with the exchange of various fluids containing detergents or enzymes to disrupt the
cell membranes and detach the cells from their underlying extracellular matrix. The detergents
are then removed by washing steps. Hypotonic and hypertonic solutions may be used to further
disrupt the cell membranes by osmotic shock. Sterilization may be performed prior to
recellularization using antibiotics and acidic solutions. Various processes requiring different
solutions, times, number of steps, or order of the reagents have been investigated as summarized
in Table 1-1.
During the decellularization process, the cells are disrupted and detached from the
basement membrane protein structure, or ECM. Detergents are perfused through the vascular
network of the organ to solubilize cell contents and membrane components. Lipids, sugars,
soluble proteins and DNA are removed. Insoluble proteins, such as collagen, laminin,
fibronectin, and elastin that form the structural features remain, as well as some signaling
molecules that are important for guiding tissue regeneration after recellularization. All of these
changes result in a tissue construct that is uniquely modified by the process. Standardization of
the process, and the use of common assays to confirm the results, are required to create a fully
5

functional human heart replacement. The reduction of time is a critical factor for optimization in
the decellularization process, in order to limit damage to the ECM by exposure to the detergents,
reduce the risk of contamination, and minimize material and labor costs.
The first report of perfusion decellularization of whole hearts was by Ott and Taylor et
al. in 2008 [2]. In their study, they used sodium dodecyl sulfate (SDS) to decellularize rat hearts
for 12 h, followed by 15 min of deionized (DI) water, then Triton X-100 for 30 min to remove
SDS and renature the ECM. Phosphate buffered saline (PBS) with antibiotics was then perfused
through the heart for 124 h. This group demonstrated that a rat heart could be decellularized to
form an ECM scaffold that could be re-seeded with a recipient’s cells and grown into a
functional heart. They also compared different methods for decellularizing rat hearts using SDS,
Triton X-100 and polyethylene glycol. They concluded that SDS was most effective in removing
cells from the heart, but challenges remained, including removal of excess SDS from the matrix.
After decellularization, they recellularized the rat heart with freshly isolated neonatal cardiac
cells through intramural injection. Perfused organ culture was maintained for 8–28 days. By day
8 after cell seeding, they reported that the heart constructs showed electrical and contractile
responses to stimulations and heart beats were observed.
Since the pioneering work of Ott and Taylor et al. [2] to decellularize and recellularize rat
hearts, multiple groups have applied decellularization technology to rat (13-17), mouse [19, 20],
pig [21-26] and even human hearts [5, 27-29]. For example, Sanchez and Taylor et al. reported
the decellularization of 23 whole human hearts with SDS for 4-5 days [28]. Guyette and Ott et
al. also reported the decellularization of porcine and human hearts [27, 29].
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Table 1-1. Summary of Decellularization Protocols of Heart Tissues
Species

Rat

Decell
time
(Days)

Total
time
(Days)

Ref
#

DI water, 1% TX-100,
Antibiotic solution

0.5

6

[2]

8mM CHAPS , 1.8mM SDS (in 1M NaCl,
and 25mM EDTA, PBS)

12% FBS endothelial
growth media

2

4

[15]

None

1% SDS (w/v)

DI water, 1% TX-100, PBS

0.8

1

[16]

Heparinized PBS, 10mM
adenosine

1% SDS (w/v), 1% SDC (w/v), 0.05%
NaN3 in DI water; 1% Saponin, 0.05%
NaN3 in DI water

20% glycerol, 0.05% NaN3,
25mM EDTA in 0.9% NaCl,
DI water, 200 IU/mL
DNase, MgCl in PBS

0.5

1.5

[17]

Heparinized PBS, chilled
PBS

1% SDS (w/v) in PBS

10% DMSO in PBS

1

1

[18]

PBS

1% SDS (w/v)

DI Water, 1% TX-100,

0.5

1

[3]

0.5

4

[19]

Pre-Decellularization
Solutions

Decellularization

Post-Decellularization

Solutions

Solutions

Heparinized PBS, 10 µM
adenosine

1% SDS (w/v)

PBS containing 1%
Pen/Strep

Antibiotic solution, MCDB131 medium
DI water

1% SDS (w/v)

DI Water, 15 min, 1% TX100,
5% Penicillin-Streptomycin
in PBS, DMEM

Mouse
DI water, PBS,

0.2% Trypsin/EDTA; 1% SDS (w/v) in
NaN3

Peracetic acid, ethanol,
PBS, DI Water

0.03

0.1

[20]

0.01% Peracetic acid, 4%
ethanol, PBS

0.1

0.33

[21]

-80°C

DI water, 2X PBS, 0.02% Trypsin in EDTA
and NaN3, 3% TX-100, 4% SDC, DI
water, PBS

PBS, 2% Pen/Strep,
amphotericin-B

1.1% NaCl, 0.7% NaCl, 0.02% EDTA,
0.05% Trypsin, 1% TX-100, 0.1% NH4OH

Sterile saline, 70% ethanol

3

4

[22]

DI water,

DI water, 2X PBS, 0.2% Trypsin in EDTA
and NaN3, 3% TX-100, 4% SDC, DI
water, PBS

0.01% Peracetic acid, 4%
ethanol, PBS

0.1

0.5

[23]

PBS

0.1% SDS (w/v), 0.01% Trypsin, 1 mM
PMSF

70% ethanol

2

18

[24]

PBS, -80°C

0.02% Trypsin, 0.05% EDTA, 3% TX-100

None

7

8

[25]

DI water, -20°C

DI water, 0.5% (w/v) SDS

None

1

1

[26]

-80°C
Water,

Pig

-80°C, 2X PBS

CHAPS: 3- [(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate; DI: Deionized water;
EDTA: ethylenediaminetetraacetic acid; PBS: phosphate buffered saline; PMSF:
phenylmethylsulfonylﬂuoride; SDC: sodium deoxycholate; SDS: sodium dodecyl sulfate;
TX-100: Triton X-100
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The methods used for decellularizing human hearts were developed based on published
protocols by the same authors for decellularizing hearts from rats [2] and pigs [21]. Retrograde
perfusion of 1% (wt/vol) SDS through the aorta was performed after perfusing the organs with
heparin solution at constant pressure of 60 mm Hg. Triton X-100 and PBS were then perfused
through the hearts to complete the decellularization and remove detergents [30]. All steps were
performed aseptically to prevent contamination of the organs. The sections below review the key
papers that have reported results for decellularizing whole mammalian hearts.
1.2

DEVELOPMENT OF DECELLULARIZATION PROTOCOLS IN RODENT MODELS

Heart models were first developed using rodent models since large numbers are available
commercially, and the small size gives better control of the decellularization environment with
fewer cells required for recellularization. Fischer F344 [2, 15], LEW/crl [17], Wistar [31, 32] and
Sprague Dawley [16, 18] rats, average body weight of 300 g, have been used in these studies as
well as mice with average body weight of 30 g [19, 20].
One of the key concerns in the use of decellularized organs has been the recipient
immune response to residual proteins, DNA and cell debris remaining in the ECM. Although
ECM proteins are considered non-immunogenic for transplantation, DNA residues more than 50
ng per mg of lyophilized tissue and residual cell proteins in tissues can induce negative immune
responses in the host body [23, 33]. Gui et al. [15] used serum nucleases to remove residual
DNA from decellularized tissues. Harvested hearts from Fischer F344 rats were cut along the
longitudinal and circumferential axes, then incubated with CHAPS, SDS buffers and endothelial
growth media (EGM) containing 2.5 to 12% fetal bovine serum (FBS) for 22, 22, and 48 h,
respectively. A significant decrease in the amount of residual DNA was observed in samples
treated with FBS. Quantification of β-actin, an indicator of residual cytoplasmic proteins, was
8

used to evaluate treatment efficacy. From these studies, the use of detergents combined with
rinses containing serum nucleases was superior in removing cell debris as indicated by the
significantly lower amounts of β-actin remaining in the samples. Additional research will be
required to confirm that these steps remove all immunogenic components.
In 2012, Witzenburg et al. [16] examined the effect of decellularization on mechanical
characteristics of the right ventricles of rat hearts. Hearts were harvested from adult female
Sprague Dawley rats (9–13 wks of age) with fresh hearts serving as controls for comparison to
decellularized hearts treated with 1% SDS over 20 h. Strain tracking was performed within 48 h
of dissection of the heart samples on a biaxial system and Verhoeff’s stain was applied to
examine the epicardial surface. From these tests, it was concluded that although decellularization
produces quantitative differences in modulus, decellularized tissue still provides a useful model
of the native tissue extracellular matrix. Further studies will be needed to confirm that
decellularization processes will not detrimentally impact the mechanical structure of the porcine
hearts that are similar in size and anatomy to human hearts.
Akhyari et al. [17] compared three published protocols [2, 21, 34] with a novel protocol
developed for whole heart decellularization of LEW/Crl rats. Searching for an ideal protocol for
myocardial decellularization, they introduced a protocol using SDS, sodium deoxycholate
(SDC), glycerol and saponin as detergents. Examining the decellularized hearts for remaining
noncollagenous proteins and residual DNA content, as well as preservation of GAGs and
viability of C2C12 myoblasts after reseeding in the ECM, they concluded each protocol had its
advantages and disadvantages. Comparing all four protocols it was shown that none of the
analyzed protocols produced a biological matrix entirely free of donor cell material and a
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scaffold with preserved ECM components. This study demonstrates the need for careful removal
of cells to avoid damaging the ECM.
Crawford et al. [18] reported successful recellularization of decellularized Sprague
Dawley rat hearts after long term cryopreservation, to determine if long intervals between
decellularization and reseeding with cells might be a viable option for commercial scales. In their
study, hearts were harvested from Sprague Dawley rats, flushed with 2500 units of heparin in
PBS, then decellularized with 1% SDS in PBS for 24 h, and cryopreserved at -80°C with 10%
DMSO in PBS. After up to 1 yr, the hearts were thawed, treated with 1% Triton-X 100 in DI
water, washed with DI water, and incubated in 6.7 U/ml nuclease at 25oC for 1 h. For
decontamination, the samples were placed in 0.1% peracetic acid and 4% ethanol for 20 min and
soaked in medium with FBS for 1 h to prepare for recellularization. Cell seeding was then
performed by injecting 2×107 canine endothelial cells with an 18 gauge needle directly through
the myocardium at 5 mm spacing. The hearts were incubated under static conditions for 45 min
and then moved to the recellularization bioreactor at 37oC and 5% CO2, then growth medium
was pumped through the heart for nine days. No DNA testing was reported for these
decellularized samples to ensure complete removal of residual DNA; however, to ensure nontoxicity of the samples, canine peripheral blood progenitor cells were grown in contact with
decellularized fragments in culture wells, and when compared with wells without tissue
fragments, no differences in cell proliferation were observed, signifying no gross, growthimpeding toxicity. This study is an example of the successful use of cross-species cells and
scaffolds. It provides encouragement for the use of porcine hearts with human cells.
Ng et al. used the same techniques and decellularized the hearts of 9-12 week old male
FVB/N mice [19]. The decellularization was initiated with overnight perfusion of 1% SDS in
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distilled water followed by washing the decellularized organ with TX-100 in distilled water for
1.5 h to remove the SDS residue. Disinfection was accomplished by perfusing the decellularized
hearts with a solution of 5% penicillin-streptomycin in PBS for 72 h at 4 °C. Then the hearts
were reseeded by retrograde aortic injection with 3×106 human embryonic stem cells (hESC) and
human mesendodermal cells (hMECs) derived from hESCs. After 14 weeks of static culture in
H9c2 conditioned cell medium (Dulbecco's Modified Eagle's Medium with 10% fetal bovine
serum, 2 mM glutamine and 1% Pen/Strep), the hearts were implanted subcutaneously into
severe combined immunodeficiency mice and then the hearts were dissected and characterized
after 2, 4 and 6 weeks. They reported that the stem cells expressed cardiac specific markers such
as cTnT, Nkx-2.5, Myl2, Myl7, Myh6 and CD31; however the beating function was lacking.
In another use of cross-species ECM and cells, Lu et al. reported the use of human iPSCderived cardiac progenitor cells in mouse hearts [20]. The optimal decellularization procedure
was completed in less than 2 h and after 20 days of culture with cardiac multipotent stem cells
derived from human iPSC (Y1-iPSCs), the hearts began to beat. Differentiation into cardiac
myocytes, smooth muscle and endothelial cells on the ECM was reported and it was shown that
ECM stimulates the proliferation of cardiac myocytes for a longer period of time than in 3D
environments without ECM. Also the effect of isoproterenol on the beating recellularized hearts
was tested and demonstrated an increase in beats per minute by a factor of 2.
In summary, in studies performed in rodent models to date, whole hearts have been
successfully decellularized and recellularized with endothelial cells to prevent thrombosis and
heart muscle cells to produce contractility. When these hearts are transplanted, however, the
pumping force of the implanted heart is not sufficient to sustain life, and the endothelialization is
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incomplete, leading to potential thrombosis in the absence of anticoagulants, and the possibility
of hemorrhage when anticoagulants are used.
1.3

DEVELOPMENT OF DECELLULARIZATION PROTOCOLS IN PORCINE
MODELS

Although Ott and Taylor mentioned in their original report [2] the attempt to
decellularize a porcine heart, they did not provide details. Several other groups have
subsequently attempted the decellularization of porcine hearts [21-26]. In general, the same
concentrations of detergents and solutions used for murine hearts have been used for porcine
hearts. Solution volumes have been increased, but exposure times have been optimized to less
than 1 day. Summaries of five different protocols for porcine hearts are given below.
In the first report of porcine heart decellularization, Wainwright et al. [21] attempted
decellularizing a porcine heart with a complex protocol in order to achieve an intact ECM
scaffold. In this procedure, the hearts were frozen at -80°C for at least 16 h for convenience of
storage and to aid in cell lysis. The hearts were then thawed in type 1 distilled water (containing
<0.1 mg/kg solids and <10 colony-forming units of bacteria/mL) at room temperature. The aorta
was cannulated with a ½” to ¼” straight barbed reducer and connected to ¼” internal diameter
(ID) silicone tubing. Each heart was placed in a 4L beaker containing 3L of hypotonic water that
was recirculated using a peristaltic pump for 15 min at 1 L/min. The water was replaced with 2X
PBS at 1 L/min for 15 min. Three liters of 0.02% trypsin, 0.05% ethylenediaminetetraacetic acid
(EDTA) and 0.05% NaN3 solution were warmed to 37°C using a digital hotplate and then
perfused through the myocardial vasculature at 1 L/min for 2 h. A 3% Triton X-100, 0.05%
EDTA and 0.05% NaN3 solution was then used for perfusion followed by a 4% SDC solution at
1.3 L/min each for 2 h at room temperature. After each chemical solution was used as a
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perfusate, type 1 reagent grade water was perfused through the heart for approximately 5 min
with no recirculation followed by recirculating 2X PBS for 15 min to aid in cell lysis and
removal of cellular debris and chemical residues.
Eitan et al. [22] decellularized 3 mm thick ring samples dissected from the left ventricle
of hearts harvested from slaughter-weight female pigs. The samples were incubated for 48 h in
1% Triton X-100 + 0.1% NH4OH in PBS solution followed by washes in sterile saline solution,
followed by immersion in 70% ethanol overnight for decontamination. The effects of
decellularizing a porcine heart and reseeding with adult sheep cardiac fibroblasts, newborn
Sprague Dawley rat cardiac myocytes and mesenchymal stem cells on mechanical properties
were examined, and these studies showed the viability and proliferation of cells from various
species on decellularized samples. DNA or cell residue assays were not performed on these
decellularized tissues to ensure complete removal of DNA and cell debris; however, in order to
indicate the biocompatibility of these samples, they measured the stimulation of macrophages in
vitro using basal nitrite concentration to demonstrate one aspect of their sample’s
biocompatibility.
Remlinger et al. [23] reported a whole porcine heart decellularization based on the
protocol of Wainwright et al. Their modification was adding cycles of hypotonic/hypertonic
solutions with type 1 distilled water and 2X PBS each for 10 min. They also increased the total
enzyme and detergent exposure time from 6 h to 8.5 h, and increased total decellularization time
after thawing the hearts from less than 8 h to more than 12 h. Using a Pico Green assay, they
reported 350 ng DNA per mg of native ventricles and less than 50 ng DNA residues per mg of
lyophilized decellularized heart, representing a significant decrease in residual DNA. Although
DNA lengths of less than 200 base pairs (bp) and total content less than 50 ng/mg have been
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proposed as acceptable threshold levels for DNA residues after decellularization [8, 35], it has
not been shown that reductions in DNA levels lead to improvements in recellularization or
acceptance by the host. Further work is required to demonstrate the effect of residual DNA on
the performance of recellularized hearts.
Wang et al. [24] reported the decellularization of sections from porcine hearts in a
rotating bioreactor. The bioreactor stimulated decellularized myocardium samples in square
shapes both mechanically and electrically, and was used to improve differentiation of stem cells
into myocardiac cells and recellularization of samples. They decellularized 20×20×3 mm
myocardium sections with 0.1% SDS, 0.01% trypsin, 1 mM phenylmethylsulfonylﬂuoride
(PMSF) as a protease inhibitor, 0.2 ug/ml RNase and 0.2 mg/ml DNase in the presence of 100
U/ml penicillin and streptomycin for 2.5 weeks, renewing the solution every 2 days. Cell
viability, histology and immunofluorescence staining were performed to confirm the presence,
number and phenotype of cells following reseeding. The differentiated cells expressed myosin
heavy chain, cardiac troponin T and sarcomeric α-actinin, indicative of a CMs phenotype. The
rotating bioreactor maintained long-term viability of cells in a sterile environment with the
ability to provide mechanical and electrical stimulus.
Merna et al. [25] reported the use of optical imaging to predict the change in mechanical
properties during decellularization of porcine hearts. Each heart was frozen at -80oC, then
thawed and decellularized with 0.02% trypsin and/or 3% Triton X-100 solutions containing
0.05% EDTA and 0.05% NaN3 for 1 to 7 days. Multiphoton microscopy (MPM) combined with
image correlation spectroscopy (ICS) were used to noninvasively characterize the mechanical
properties of the hearts. It was found that Triton X-100 preserved the collagen matrix, whereas
trypsin weakened the heart structure.
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Some important lessons have been learned from the prior work on optimization of
decellularization. For example, trypsin or other enzymes are typically used to detach cells from
surfaces, including tissue culture polystyrene. In employing the use of enzymes to remove cells
from the whole organ extracellular matrix, there is a concern that damage may occur to the ECM
or insoluble signaling proteins. The paper by Merna et al. [25] showed that trypsin weakened the
heart tissue more than Triton X-100. Also, DNAse was used to break up and remove the DNA
that could be potentially immunogenic. Several papers have indicated, however, that the removal
of DNA by detergents such as SDS and Triton X-100 is sufficient, and the presence of low
amounts of DNA is not considered an impediment to recellularization or of concern for
immunogenicity [9]. This conclusion was based on the studies by Keane et al. [36] that described
similar cell behavior on fully decellularized scaffolds compared to those after incomplete
decellularization. Additional work is required to verify this conclusion. Overall, while there are
various methods that have been successful for decellularization, the combination of SDS and
Triton X-100 appears to be the best method reported so far. SDS is a strong ionic detergent that
is very effective at removal of cells, but persists in the ECM. Triton X-100 is very effective at
removing SDS and remaining cell debris. In my experience, retrograde perfusion with 3 batches
of SDS for 2 h each, alternating every 2 h with DI water, and then perfusing with Triton X-100
for 4 hours, followed by extensive rinsing in DI water for at least 4 hours, produces a completely
decellularized porcine heart.
1.4

STRATEGIES FOR RECELLULARIZATION

The process of recellularization involves the selection and proliferation of cells, as well
as the provision of nutrients, growth factors, gases and waste exchange in a bioreactor. Many cell
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types [3, 19, 20, 37-62] from autologous and allogeneic sources have been proposed for use in
recellularization (Table 1.2).
It may be necessary to provide co-cultures of multiple cell types, or if a pluripotent cell
type is selected, it may be possible for that single cell type to differentiate into all the cell types
of the heart. Early attempts to engineer heart valves identified the aortic valve interstitial cells
[46], saphenous vein cells, and myofibroblasts [47] as potential cell sources. Cells that have been
specifically considered for whole heart engineering include embryonic stem cells [58], skeletal
myoblasts, resident adult cardiac stem cells, adipose-derived stem cells, peripheral blood
mononuclear cells, bone marrow-derived hematopoietic and mesenchymal stem cells [59] to
provide contractility and to produce extracellular matrix proteins during tissue repair and
remodeling. CMs are required to populate the thick portions of the heart muscle; fibroblasts are
required for generation, maintenance and repair of the extracellular matrix; and endothelial cells
are required to line the flow surfaces. In addition, smooth muscle cells that form the walls of
blood vessels and pacemaker cells that control the heart rhythm must also be reintroduced. Care
must be taken to prevent contamination from bacteria and fungi during recellularization, storage
and handling prior to implant. Ideally, the patient’s own (autologous) cells would be used,
however this would most likely require the isolation and culture expansion of cells in a facility
that is capable of simultaneously handling human cells from many patients under strict controls.
Alternatively, allogeneic cells could be used, but they would need to be carefully selected or may
require surface modification to prevent the cells from initiating an immune response.
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Species

Murine

Table 1-2. Cell Sources for Regenerative Medicine

Cell type
Transdifferentiated fibroblasts into
cardiomyocytes without inducing
pluripotency
iPSC
Transdifferentiated
iPSC
STAP
Cardiac telocytes
Neonatal cardiomyocytes, RAEC

Murine/Human

iPSC
hESC, mouse cardiac cells

Porcine

Aortic valve interstitial cells
ESC
iPSC
Saphenous vein endothelial cells and
myofibroblasts
Stem cells
iPSC
iPSC
iPSC

Human

iPSC
CPC
iPSC
Macrophages
Fibroblasts
Endothelial cells
ASC, BMMNC, MSC, ADSC, HFSC,
UCSC, MDSC, EPC
ASC, ESC, iPSC, BMMNC, PBMNC
ESC, BMAPC, MSC, HSC
iPSC
ASC, ESC, iPSC

Comments
Direct reprogramming may be the most promising approach

Immunosuppression enhances engraftment
Inefficient to reprogram
High quality iPSC differentiate better
Low pH induces pluripotency
Injecting telocytes improved the function of hearts after infarction
Cardiomyocytes were injected into the decellularized scaffold, RAEC were
infused through the brachiocephalic artery and vena cava of
decellularized rat hearts
Viral infection and correct stoichiometry of 4 transcription factors affect
efficiency
Combined cells with urinary bladder matrix for cardiac repair
Primary cells were obtained from porcine leaflet explants and reseeded
onto decellularized heart valves
ESCs were differentiated into hMEC and cardiac cells in decellularized
mouse hearts
Cells were differentiated into cardiac progenitor cells, EC, SMC and
cardiomyocytes in decellularized mouse hearts
Decellularized porcine heart valves were reseeded with human cells

Ref(s) #
[37]

[38]
[39]
[40]
[41,
42]
[43]
(17)

[44]
[45]
[46]
[19]
[20]
[47]

Umbilical cord matrix was proposed as a source of stem cells
Sendai RNA virus is efficient, and doesn’t integrate into host
Progress toward virus-free iPSC
Need to increase efficiency, reduce risk of teratoma, develop methods for
cell delivery
High purity enrichment by FACS
Genetic modification
Cardiomyocytes useful for drug screening, toxicity studies
Macrophages are a primary responder after myocardial infarction
Fibroblasts are the most abundant cell in the myocardium
A functional non-thrombogenic layer of EC on collagen was constructed
Sources for stem cells

[48]
[49]
[50]
[51]

Many cells types are available for potential use in tissue engineering
cardiac tissue
Differentiation agents for hESC
Useful for understanding disease mechanisms, screening new drugs and
cell replacement therapy
Describes 4 ways to engineer organs

[59]

[52]
[53]
[54]
[55]
[56]
[57]
[58]

[60]
[61]
[62]

ADSC: adipose-derived stem cell; ASC: adult stem cells; BMAPC: bone marrow-residing adult
progenitor cells; BMMNC: bone marrow mononuclear cells; CPC: cardiac progenitor cells; EC:
endothelial cells; EPC: endothelial progenitor cells; ESC: embryonic stem cells; HFSC: hair
follicle-derived stem cells; HSC: hematopoietic stem cells; iPSC: induced pluripotent stem cells;
MDSC: muscle derived stem cells; MSC: mesenchymal stem cells; PBMNC: peripheral blood
mononuclear cells; RAEC: rat aortic endothelial cells
Several articles have highlighted the progress and challenges associated with culturing
cells for regenerative medicine [3, 19, 20, 37-54, 58-62]. Five of these papers specifically
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reviewed the use of stem cells for cardiovascular engineering [58-62]. Since these reviews were
published, multiple papers have addressed the unique issues pertaining to the use of iPSC, which
may ultimately be the best solution to provide patient-specific cells, but will require
improvements in efficiency of de-differentiation, the elimination of the risk of teratoma
formation, improved culture techniques, and novel methods for delivering the cells to the
decellularized matrix.
An alternative to the use of iPSC may be the transdifferentiation of fibroblasts directly to
CMs without inducing pluripotency. This has been demonstrated by Ieda et al. [37], in which 3
developmental transcription factors (Gata4, Mef2c, Tbx5) were found to efficiently (20%)
reprogram cardiac fibroblasts into CMs in 3 days without inducing a pluripotent state. However,
Chen et al. attempted to replicate this method with contrary results [39].
Bajpai et al. [58] and Jing et al. [60] also have reviewed the potential and challenges of
stem cells for repairing damaged heart tissue. Stem cells are unique in that a certain fraction
proliferate and retain their “stemness” while others differentiate. Types of stem cells include
embryonic, bone-marrow residing adult progenitor cells, side population, cardiac stem cells,
skeletal muscle progenitors (satellite cells), and adipose-derived stem cells. Liu et al. [62]
described four ways to engineer organs: from a single stem cell, injecting stem cells into
blastocysts, using a decellularized tissue scaffold plus stem cells, and combining stem cells with
synthetic scaffolds.
There are many advantages to the use of iPSC, including the avoidance of political and
ethical issues related to embryonic stem cells. The discovery of the Yamanaka transcription
factors (Klf4, Sox2, Oct4 and c-Myc) has allowed many labs world-wide to study iPSC. Cell
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lines are now available for many diseases and cell types [50]. Some of the challenges of using
iPSC are the low efficiency, need for viral infection, and the possibility of teratoma formation
[44]. IPSC from various sources demonstrate variable efficiencies. Recent reports have claimed
efficiencies in the creation of iPSC of greater than 90% after enrichment through cell sorting
[52]. There are also recent reports that a low pH environment may be sufficient to produce
pluripotency [41, 42].
Many other investigators have examined various ways to improve the performance of
cells on engineered substrates. For example, the culture environment for endothelial cells has
been shown to have a major role in whether anti-thrombogenic or pro-coagulation factors are
produced [57]. In addition, Le et al. [63] described the surface roughness needed to control
protein and cell attachment. Higuchi et al. [64] demonstrated that heart matrix supports CMs
attachment. Tosun and McFetridge [65] proposed the use of gradients to improve cell seeding,
and Daly et al. [66] discussed the initial binding of cells during recellularization.
Recently, telocytes, a type of interstitial cell that are found in myocardium, epicardium,
endocardium and in cardiac stem cell niches, were discovered. Though the functional role of
these cells in myocardial tissue is not completely understood, it has been shown that they play an
essential role as niche-supporting cells that nurse the cardiac stem cells and angiogenic cells in
the myocardium [67, 68]. Zhao et al. [43] showed that cardiac telocytes can be identified using
CD34 and c-kit markers as well as morphological techniques. They reported that 4 days after
myocardial infarction, the number of telocytes in the heart are highly diminished, and injecting
them back into the damaged hearts improved the function and reduced the size of scar tissue in
the rat hearts.
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In order to reduce the thrombogenicity and improve the function of the recellularized
hearts, Robertson et al. [3] recellularized rat hearts that were decellularized based on the
previous protocol described by the same group [2] with rat aortic endothelial cells (RAEC) and
neonatal CMs. They infused either 2×107 or 4×107 cells to the decellularized hearts from the
brachiocephalic artery (BA), aorta or inferior vena cava (IVC). During the infusion from the
aorta, retrograde perfusion of media was stopped for 1 h. Alternatively, endothelial cells were
infused to the heart from the BA without any breakage in the MCDB-131 media perfusion. They
reported that cells delivered only via the aorta were not uniformly distributed throughout the
heart and the best result was delivering the cells through the IVC and BA simultaneously. Using
both BA and IVC they observed that the endocardial surface of the left ventricle was
predominantly recellularized with RAECs delivered via the BA, whereas the endocardial surface
of the right ventricle was populated with RAECs delivered via the IVC. After 7 days of RAEC
culture, they injected 1.3×108 rat neonatal cardiac cells into the left ventricular wall in three to
four parallel injections. One day afterwards, electrodes were sutured to the apex and base of the
hearts in order to stimulate the cardiac function. After 10 days of culture, a microtip pressure
catheter was inserted into the left ventricle and the pressure generation by the cells was
monitored. They observed that the pressure generated by the heart, at 4 Hz of stimulation was 6
times higher in hearts that were cultured with RAECs prior to recellularization with CMs.
Challenges remain in selecting human cell types for use in cardiac tissue engineering.
These include: combining cells with ECM proteins, promoting cell migration and homing to the
proper location in the pre-existing ECM, ensuring electromechanical cell coupling for
propagation of depolarization potentials, producing a robust and stable contractile function, and
proper vascularization of the tissue [59]. Challenges also remain with the use of stem cells due to
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the possibility of teratoma formation, the need to culture and maintain large quantities of viable
cells, and the necessity to deliver the cells in a manner that is conducive to their survival and
integration into the heart. If stem cells are combined with a decellularized matrix, there is also a
need for the addition of growth and differentiation factors (Table 1.3), bioreactors designed to
properly condition the heart so it is ready for transplant (Table 1.4), evaluation of the heart prior
to implant (Table 1.5), and methods to integrate the heart into the body so it can perform its
function. Another major challenge is the prevention of thrombus formation (Table 1.6).
1.5

GROWTH AND DIFFERENTIATION FACTORS

Soluble trophic factors may be delivered during the growth of the tissues to promote
differentiation or proliferation. Generally fetal bovine serum is added in cell culture, although the
elimination of as many unknowns as possible has led multiple researchers to develop xeno-free
formulas of cell media. In the case of adding growth factors to the porcine hearts, testing of the
combination of factors and possibly their sequence of administration will be necessary to identify
potential regeneration factors and eliminate immunogenic factors. Some of the growth and
differentiation factors used in tissue engineering [20, 69-77] are listed in Table 1-3.
Critical factors [78] that have been identified for evaluation include basic fibroblast
growth factor (bFGF) [20, 69], transforming growth factor beta 1 (TGFβ1) [70, 71], vascular
endothelial growth factor (VEGF) [20, 72], hepatocyte growth factor (HGF) [72], plateletderived growth factor (PDGF) [74, 75], bone morphogenetic protein (BMP) [76], and
angiopoietin-1 [77].
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Table 1-3. Growth and differentiation factors

Factor

Purpose

Comments

Ref #
[20]

BMP-4, Activin A,

iPSC-derived cardiac progenitor stem cells,

Cardiac progenitor stem cells were derived from iPSC

bFGF, VEGF,

endothelial cells, smooth muscle cells and cardiac

in culture flasks and then differentiation into various

DKK1

myocytes differentiation

cardiac cells was done in the accellular ECM of a
mouse heart

bFGF

Induces the proliferation of endothelial cells,

bFGF was released from alginate with initial 40%

fibroblasts, smooth muscle cells, and hepatocytes

burst followed by sustained delivery, increasing

[69]

vascularization of alginate scaffold
Mediator of inflammatory and fibrotic response

TGFβ1

VEGF

Regulates new vessel growth

Mediates the cardiomyocyte proliferation and

[70,

production of ECM by fibroblast

71]

PEG scaffolds releasing VEGF were completely

[72]

remodeled into vascularized tissue
HGF

PDGF

BMP

Angiopoietin-1

Mitogen of hepatocytes, increases proliferation of

HGF bound by a collagen binding domain from

endothelial cells but not vascular smooth muscle

fibronection was released from a collagen sponge,

cells

increased vascularization

Multiple roles in growth of fibroblasts, SMC, and

PDGF was shown to be effective in periodontal

[74,

glia cells; also implicated in various diseases

regeneration

75]

Critical to development and differentiation of cells

Fibroblasts were found to differentiate into

[76]

to cardiomyocytes

cardiomyocytes by BMP

Regulates vascular integrity and quiescence

Provides a connection between quiescient and active

[73]

[77]

endothelial cells

bFGF: basic fibroblast growth factor; BMP-4: bone morphogenetic protein-4; DKK1: Dickkopfrelated protein 1; HGF: hepatocyte growth factor; PDGF: platelet-derived growth factor; TGFβ1:
transforming growth factor beta 1; VEGF: vascular endothelial growth factor
The temporal and spatial distribution of the factors is important, and encapsulation or
controlled release strategies of the factors may be required. Lee et al. [79] found that synthetic
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particles that released VEGF in response to mechanical stress could control blood vessel density
in newly forming tissue.
Freeman et al [80] demonstrated that the release of bFGF from alginate hydrogels
doubled the formation of blood vessels, and Harel-Adar et al. [80, 81] showed that modulation of
cardiac macrophages by phosphatidylserine-presenting liposomes improved infarct repair.
1.6

BIOREACTOR DESIGNS

Pre-conditioning of the organ with a physiologically relevant set of conditions must be
performed prior to implant. Bioreactors that can operate in a range of temperatures, from room
temperature to 37oC, allow for gas exchange, and provide nutrients during the growth phase have
been designed [82]. For hearts, the muscle must be allowed to grow and organize, and then be
subjected to flow conditions that mimic normal blood flow dynamics in order to strengthen the
muscle until it can perform its function of pumping with the appropriate force. One particular
challenge with hearts is incomplete perfusion due to trabeculated atrial appendages that are
potentially difficult to perfuse. For example, the left atrial appendage (LAA) has a narrow,
sharply pointed shape. It is believed to function as a decompression chamber during left
ventricular systole and other periods when left atrial pressure is elevated, and it has endocrine
function as the primary source of atrial natriuretic factor (ANF). In contrast, the right atrial
appendage is broad-based and less distinct in appearance, with trabeculations (pectinate muscles)
that extend toward the tricuspid valve and are not confined to the appendage [83]. Al-Saady et al.
[84] posited that obliteration or amputation of the LAA may help reduce the risk of
thromboembolism in patients with primary cardiac disease, but this may result in undesirable
physiological sequelae such as reduced atrial compliance, reduced secretion of ANF in response
to pressure and volume overload, and decreased stroke volume and cardiac output that may
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promote heart failure. Bioreactor designs must be robust, and potentially may need to include
sensors to detect flow rates and pressures to provide a means to compensate for changes related
to the presence of atrial appendages, while optimizing flow to help minimize thrombogenesis.
Several investigators have proposed various designs [2, 31, 85-87] for bioreactors (Table
1.4). Bioreactors that are able to create high pressure at the coronary arterial orifices should be
used to ensure that the atrial appendages will have sufficient flow in the vessels so that they can
be decellularized and recellularized completely.
Decellularization is often performed in a modified Langendorff apparatus [2] with
retrograde perfusion preferentially used over antegrade flow. Geeslin et al. [86] discussed the
bioreactor designs for vascular conduit regeneration, including duel reservoirs for endothelial
cells and smooth muscle cells. These were connected in parallel with pumps and oxygenators.
The smooth muscle cells were cultured on the exterior of a decellularized matrix, while the
endothelial cells were cultured on the lumen. Avci-Adali et al. [87] discussed a rotating
bioreactor based on ready-to-use medical disposables to re-endothelialize a vascular conduit.
Their results demonstrated that ePTFE grafts with albumin and heparin coatings produced the
most extensive endothelial cell adhesion and spreading.
Bursac et al. [85] discussed rotating bioreactors for culturing CMs in 3D cultures. They
found that cells cultured in 3D created better tissue than in 2D monolayers. Huelsmann et al. [31]
applied the concept of 3D stretching to provide mechanical stimulation to a whole decellularized
heart matrix from Wistar rats. Their device included an inflatable latex balloon inserted into the
left ventricle and inflated by a syringe pump, and was controlled with a pressure sensor and
LabView software. Hearts seeded with C2C12 murine myoblasts were cultured for 24 h in static
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culture, and with biomechanical stimulation for another 72 h. Although the results demonstrated
lower cell viability, there was an improvement in orientation of cells in the exercised hearts.
Further work will be required to optimize the development of bioreactors for whole porcine
hearts.
Size

Table 1-4. Bioreactors

Media

Comments

Mechanical Specification

Estimated Cost

Ref #

Decell:

O2, CO2, N2 in a gas mixer
with chamber controlled
pH. Mechanical stimulation
improves cell alignment.

Left ventricular 3D stretching
latex balloon, controlled with
pressure and a membrane
pump

$10,000

[31]

O2,CO2, electrodes for
stimulation of
cardiomyocytes, recording
ECG and pressure

Pulsatile flow from peristaltic
pump, Controlled pressure and
flow

$70,000

[2]

CO2, electrical stimulation
and ECG recording

Rotating bioreactors were used
to culture cardiomyocytes in 3D

$10,000

[85]

$5,000

[86]

$3 per device

[87]

SDS, SDC, NaN3,
Saponin
Recell:

250 mL
(whole rat
heart)

FCS, DMEM
Decell:
SDS, TX-100
Recell:
IMDM, FBS, HS

100 mL

Recell:

(biopsy of
porcine
heart)

DMEM, 10% FBS, HS

40 mL (rat
aorta)

2 reservoirs for
external media and
internal media

Small rotating bioreactor
that can be put in CO2
incubator

Pulsatile flow

1-2 mL (small
vascular
grafts and
stents)

VascuLife EnGS EC
culture media

Can be put in CO2
incubator, not suitable for
long cultures because of no
media perfusion

Rotated culture at 5 rpm, no
perfusion

DMEM: Dulbecco's Modified Eagle's Medium; EC: endothelial cell; EnGS: endothelial cell
growth supplement; FBS: fetal bovine serum; FCS: fetal calf serum; HS: horse serum; IMDM:
Iscove’s Modified Dulbecco’s Medium; SDS: sodium dodecylsulfate; SMC: smooth muscle
cells; TX-100: Triton X-100
1.7

EVALUATION OF ORGANS

Each type of recellularized organ (kidney, lung, heart, etc.) will require a different set of
tests to evaluate its functional performance prior to implant. For example, the proper
performance of kidneys will require that the cells filter blood and create urine. Lungs will require
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that the cells exchange oxygen and carbon dioxide with circulating blood. Hearts must be preconditioned to pump blood at physiologically relevant pressures and flow rates. Although
bioengineered recellularized organs may eventually be able to perform desired endocrine
functions, this physiologic property must be secondary, and is expected to be sacrificed during
the development of transplantable organs with adequate biomechanical function to sustain life.
Nevertheless, across all of these organs, the flow surfaces must be prepared for contact with
blood. Endothelial cells naturally perform the function of preventing thrombosis. The logical
goal of whole organ recellularization, therefore, is to fully cover every blood-contacting flow
surface with endothelial cells. Assuring that the blood-contacting flow surface has been
thoroughly re-endothelialized will require the development of strategies to measure endothelial
cell viability, coverage and functional performance in prevention of thrombosis, in addition to
other analytical tests.
Analytical methods have been identified to detect proteins [15, 17, 18], cellular debris,
and DNA content after decellularization [2, 3, 15, 17, 21, 23]. Research has also been done on
the evaluation of mechanical characteristics after decellularization and recellularization [2, 15,
16, 21, 22], demonstrating the potential for strengthening the muscles prior to implant. In
addition, Jungebluth et al. [88] has demonstrated a viability assay for cells prior to
transplantation. These strategies are summarized in Table 1-5.
1.8

STRATEGIES FOR PREVENTING THROMBOSIS

During the development of vascular grafts, intracoronary stents, the total artificial heart,
and other blood-contacting medical devices, many strategies have been proposed for preventing
thrombosis, including delivery of anticoagulants, the attachment of endothelial cells [3, 89-95]
[96-98], attachment of heparin [99], the creation of non-fouling surfaces [100-103], and other
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approaches. The use of anticoagulants (e.g., heparin) in the systemic circulation can be used to
prevent acute thrombosis, but may lead to hemorrhage over the long-term, and are not included
in this review. The other strategies are summarized in Table 1-6 and described in detail below.
Table 1-5. Evaluation Methods

Type of Analysis

Protein

GAG

Method

Criteria for Success

Ref #

Cytoplasmic protein (e.g. β-actin) removal as
detected by immunoblotting

Residual cytoplasmic proteins should
approach 0%

[15]

Noncollagenous protein content, including laminin
and elastin, detected by histology staining and
Western blotting

Less than 7% of native non-collagenous
proteins retained

[17]

Monitor total protein content in the effluent

Approach 0% after 6 hours

[18]

Total glycosaminoglycan (GAG) content

More than 200-250 µg/g preserved

(15)

Quant-iT PicoGreen dsDNA assay after using
serum nucleases to remove DNA

Residual DNA was 0%

[15]

DNA labeling with fluorescent markers

Less than 4% remains

[2]

DNA quantification kit (Qiagen, Hilden, Germany)

Less than 3 µg/g (0.5%) of native DNA
remained

[17]

Quant-iT PicoGreen dsDNA assay

Less than 8% remains

[21]

Burst pressure of human umbilical arteries

No significant difference in burst
pressure of blood vessels after
decellularization

[15]

Stress-strain test

Very similar to native

[2]

Ball burst test

Maximum force endurance the same as
native

[21]

Colorimetric method for testing tissue engineered
tracheas prior to implant

Average cell coverage of 40%

[88]

Live/Dead Assay after 24 culture with C2C12
myoblasts

>95% cell viability

(15)

DNA

Mechanical

Cell Viability

The process of preventing thrombosis is closely related to strategies for recellularization.
If endothelial cell coverage could be perfectly achieved, and inflammation during healing at the
anastomoses could be minimized, then theoretically thrombosis could be avoided. Kasimir et al.
[89] described the decellularization of porcine heart valve matrix with Triton X-100 and SDC
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(sodium deoxycholate). The scaffolds were then recellularized with human umbilical vein
endothelial cells (HUVEC) and tested with human platelets from volunteers. Platelet adhesion
and activation were measured and antibodies to collagen and elastin were used to characterize
the material. It was found that the decellularized scaffold was a platelet-activating surface.
However, seeding the surface with endothelial cells abolished platelet adhesion and activation.
They concluded that endothelial cells are essential to prevent thrombosis. Kasimir et al. [90] then
tested Synergraft valves (porcine) vs. Triton X-100 decellularized grafts. Important factors that
were identified included the α-gal epitope, monocyte migration, calcification of glutaraldehyde
cross-linked valves, and the need for complete coverage by endothelial cells to prevent platelet
activation, since platelets recruit leukocytes and express chemokines and cytokines that activate
monocytes, leading to inflammation. The removal of the α-gal epitope, present on the surface of
porcine vascular endothelium, is important since α-gal activates the classical complement
pathway, resulting in hyperacute rejection and graft failure. In addition, other
glycosaminoglycans (GAGs) can interact with cytokines and chemokines and may also need to
be eliminated to avoid an inflammatory or immune response.
Alternatively, GAGs may need to be preserved to properly attach the endothelial cells.
The GAGs are part of the local environment surrounding each cell, called the pericellular matrix
(PCM). The PCM may need to be reconstituted with the appropriate GAGs and proteins to retain
adhesion molecules and insoluble signaling molecules while also removing the immune
activating molecules. McLane et al. [94] discussed the role of the pericellular matrix on
chondrocytes and methods to noninvasively measure the ultrastructure of the hydrated zone that
extends 100 to 500 nm from the cell surface. It was concluded that the PCM mediates cell
interactions with surrounding tissue, and may influence important processes such as cell
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adhesion, mitosis, locomotion, molecular sequestration, and mechanotransduction. In
reestablishing the PCM for cardiac cells, care must be taken to first provide a nominally nonthrombogenic or non-fouling surface. The CMs and endothelial cells can then be added. If there
is a break in coverage of the endothelial cells, the platelet adhesion and activation may be
mitigated by the non-thrombogenic constituents despite the presence of the underlying
thrombogenic extracellular matrix. Lichtenberg et al. [91] decellularized pulmonary valves using
detergents, and DNAse I to remove greater than 95% of the DNA. In the decellularized
structures, collagen, elastic fibers, GAGs and basement membrane were all preserved. It was
hypothesized that the absence of endothelium may predispose the matrix surface to thrombosis.
Adhesion ligands (collagen IV, laminin, and perlecan) in the basement membrane were thought
to attract circulating endothelial cells or progenitor cells which covered the pulmonary valves.
They provided evidence that preservation of GAGs followed by reendothelialization can prevent
thrombosis and hyperplasia of tissue engineered blood-contacting structures.
Another approach has been to reattach specific GAGs to the blood-contacting surface.
For example, heparin attached to expanded polytetrafluoroethylene (ePTFE) vascular grafts has
been successful in preventing thrombosis [99]. The trade-off between controlling thrombosis
with systemic heparin, and preventing the natural healing response at the anastomoses and
pseudointimal hyperplasia in the lumen of the implant has always been a challenge for vascular
grafts. Propaten® vascular grafts successfully prevent early thrombosis due to the covalent endpoint heparin attachment method developed by Carmeda® and the high concentration of heparin
attached to the surface. Ye et al. [92] proposed the use of a polyelectrolyte multilayer film on
decellularized porcine aortic valves to prevent thrombosis. The alternating layers of heparin and
chitosan provide another method of attaching heparin to the surface to prevent the initiation of
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thrombosis. A non-thrombogenic underlayer could provide a safety factor against thrombosis if
the endothelial cell layer is incomplete or disrupted during initial or long-term use.
The use of in vitro endothelialization [96] is another proposed way to prevent thrombosis
in tissue engineered and synthetic vascular grafts. However, attempts to endothelialize vascular
grafts have generally been unsuccessful due to the cost and complexity of maintaining living
grafts during shipping and storage. Several strategies have been employed to increase endothelial
attachment. For example, fibronectin was added to decellularized aortic grafts to accelerate
reendothelialization and prevent thrombosis [97]. Wissink et al. developed a new method for
collagen crosslinking using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) and Nhydroxysuccinimide(NHS) in order to improve endothelial cell seeding on human umbilical
veins [98]. Lord et al. [100] proposed the use of perlecan (which is the main heparan sulfate
proteoglycan secreted by endothelial cells) to reduce thrombogenicity and demonstrated that
perlecan did not permit aggregation of platelets when the heparan sulfate chains attached to
perlecan were intact. Elastin has also been proposed as a non-thrombogenic material [101]. Other
non-fouling synthetic materials, including polyethylene oxide (PEO), have been proposed [102].
Similarly, Smith et al. [103] at Semprus® Biosciences (a division of Teleflex) developed a
technology to attach sulfobetaine molecules to the surface of blood-contacting devices that
minimizes thrombus formation. The Semprus® technology employed zwitterionic sulfobetaine
molecules that coordinate water near the surface of blood-contacting catheters to create a nonfouling surface. Both bacteria and platelets were prevented from attaching. All of these
approaches to improve reendothelialization could be considered for adaptation to decellularized
organs. Each approach would require further optimization, and may require new chemistry and
process conditions to provide benefit without damaging the ECM.
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It may also be possible to genetically modify the cells that are used for recellularization
to be more thromboresistant. For example, Kader et al. demonstrated that overexpression of
endothelial nitric oxide synthase (eNOS) by endothelial cells produced anti-thrombotic
conditions and decreased platelet aggregation by 46% [95]. Alternatively, some have proposed
that it may be possible to implant decellularized tissues into the recipient’s body without the
need for reendothelization. Assmann et al. [32] dissected thoracic aortas from Wistar rats and
decellularized them with four 12-h cycles of 0.5% SDS + 0.5% SDC and then rinsed the aortas
with distilled water for 24 h to wash off the detergents. The aortas were then rinsed with three
24-h cycles of 1% penicillin/streptomycin in PBS. These engineered grafts were implanted in
recipient rats and connected to their circulatory system. After 8 weeks they extracted and
examined the samples and reported a confluent luminal cell layer, purportedly from circulating
cells in the peripheral blood. Although this approach is promising, it has not been shown that
these results can be extrapolated to smaller blood vessels (<4 mm) where artificial grafts have
consistently failed due to thrombosis and hyperplasia.
In order for reendothelialization to be effective, the specific attachment of endothelial
cells to the surface may be required, while avoiding the attachment of platelets. Insoluble
signaling proteins such as fibronectin are believed to be required in order to reestablish correct
spatial orientation of cells during recellularization. Specific sequences of amino acids, such as
arginine-glycine-aspartic acid (RGD) peptides from fibronectin, are involved in cell attachment,
and if disrupted, may not permit proper positioning of the new cells on the matrix. Bellis [93]
recently reviewed the use of RGD peptides for directing cell attachment. In the late 1980’s on
through the 1990’s, a number of labs were successful in attaching RGD peptides to a variety of
surfaces to promote endothelialization [102, 104-109]. Although the first approach for specificity
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in the attachment of endothelial cells to synthetic matrices was based on the use of RGD
peptides, these peptides were found to be non-specific and also bound platelets in addition to
endothelial cells. In addition, although RGD peptides have been shown to promote the
attachment of cells in vitro, once a surface is exposed to blood the surface is rapidly remodeled
and covered by circulating proteins (Vroman effect). Therefore, combining peptides that promote
the adhesion of endothelial cells with non-fouling surfaces or non-thrombogenic molecules may
be a more likely way to succeed. The creation of a non-fouling, non-thrombogenic surface
followed by RGD, YIGSR, GFOGER, cyclic RGD, REDV, or other specific peptides to attach
endothelial cells has been proposed [93]. This approach will require further investigation. To be
successful, cells should attach, integrate, promote regeneration, and be interactive and
biomimetic. Multiple modification steps with various molecules may be needed to achieve all of
these objectives.
It is clear that in order to advance the field of whole organ decellularization and
recellularization, there are many possible ways to accelerate the processes, and there are many
variables that can be optimized. In the pioneering work of Ott and Taylor [2], an in vivo animal
model assay was used to test the performance of bioengineered hearts. It would be cost
prohibitive to test all the possible combinations of seeding strategies and to compare all of the
other variables in animal models. Therefore, rapid, reliable, and relevant in vitro assays that are
amenable to whole organ testing will be essential tools to investigate the various strategies for
recellularization and thrombosis prevention. The multiple modalities, blood components, and
conditions that affect thrombus formation on a surface necessitate concomitant sophistication in
the test methods to assess this phenomenon. For example, coagulation may be more pronounced
in areas of low flow and stagnation (e.g., atrial appendages) while platelet activation, adhesion,
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and aggregation may be elevated in regions of high shear (e.g., coronary arteries). Thus,
assessment of whole organ performance may require a diverse panel of tests to identify specific
problems that will help expedite development of a non-thrombogenic organ. The ISO 10993-4
standard prescribes such a panel of in vitro tests for the assessment of blood-contacting device
hemocompatibility [110] that may serve as a useful guide when adapted suitably for whole organ
thrombosis assessment. Assessments of fluid phase markers of coagulation cascade activation
(e.g., thrombin-antithrombin ELISA) and platelet activation (e.g., β-Thromboglobulin ELISA, pselectin expression by flow cytometry) are some of the recommended tests [111]. Evaluation of
surface-bound platelets and thrombus using radiolabeled platelets and scanning electron
microscopy are highlighted as important tests [112]. The roles of the complement pathways and
leukocytes in thrombosis have also been recognized and associated assays are considered
valuable [113].
In addition to the tests outlined in the ISO 10993-4 standard, several other test models
have been reported in the literature. Hanson and Sakariassen [114] reviewed the experimental
models of thrombosis used to measure antithrombotic drug efficacy. They demonstrated that
flow of the blood in a circuit can also activate platelets. Shankarraman, et al. [115] have utilized
thromboelastography to quantify thrombogenicity of blood-contacting surfaces. In-vitro blood
flow models have been used to assess thrombosis and thromboembolism associated with
artificial hearts and vascular implants such as stents [29, 111, 112, 116, 117]. Ensley and Nerem
[118] studied the effects of shear stress on performance of endothelial outgrowth cells.
McGuigan and Sefton [57] seeded human umbilical vein endothelial cells (HUVECs) on
collagen and developed thrombogenicity assays using whole fresh blood from consenting donors.
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They perfused constructs with blood, demonstrating that HUVECs prevented the attachment of
platelets.
In the first report of measuring thrombogenicity in decellularized whole organs, Taylor’s
research group has shown that recellularizing rat hearts with RAECs prior to adding neonatal
CMs decreases the thrombogenicity and improves the beating function of the heart [3]. In order
to measure the thrombogenicity of the recellularized organs, they examined protein C activation
as an indicator for activation of the anticoagulation pathway. After 7 days of RAEC culture they
observed a 6 to 8 fold increase in thrombomodulin and protein C activity in recellularized hearts
compared to acellular hearts. They also performed a heterotopic transplantation of the reendothelialized hearts into recipient rats that were on anti-coagulation therapy with 100 IU/kg
sodium heparin on the day of transplant and 200 IU/kg sodium heparin subcutaneous for the next
two days and daily coumadin (0.25 mg/kg) in the drinking water. After 7 days the hearts were
dissected and they reported the observation of fewer blood clots in the aortas and ventricles of
the re-endothelialized hearts compared to acellular hearts. They also observed the presence of
endothelial cells in acellular hearts that were not recellularized with RAECs before
transplantation.
Thrombogenicity of the decellularized and recellularized whole hearts can be assessed
using bovine blood with an assay [119] that has become a standard performance measurement
for the medical device industry. In this in vitro flow model of thrombogenicity, suitably
anticoagulated bovine blood is pumped through the heart at a controlled flow rate. The thrombus
that forms in the heart is characterized after a period of blood flow by high resolution digital
photography and measured by radiolabeled platelets that accumulate in the thrombus. Scanning
electron microscopy of select regions is also used to investigate the morphology of thrombi and
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to understand their origin and progression on the test surfaces. One of the unique features of
studies conducted with advanced in vitro flow models is that relevant conditions can be
controlled more precisely than is possible in animal and clinical studies [120]. Parameters that
significantly influence thrombosis such as hemostatic conditions (i.e., anticoagulation) can be
controlled precisely in the in vitro setting. Yet another benefit of an in vitro setting is the ability
to directly quantify thrombosis (e.g., with Indium-labeled platelets). In future studies, the in vitro
blood flow model can be used to assess thrombogenicity of tissue engineered hearts and test the
effect of various decellularization process conditions and cell sources.
For these studies, fresh blood is obtained by inserting a cannula directly into the heart of
cows during exsanguination at a local abattoir and collected into a collapsible reservoir
containing an anticoagulant (heparin or sodium citrate). The negative controls in these studies are
fully decellularized hearts that would be expected to have a very high amount of thrombus
formation. The positive controls are freshly harvested hearts prior to decellularization that would
be expected to have a low amount of thrombus formation. The test hearts are decellularized
under various conditions, modified with non-thrombogenic molecules, and optimally
recellularized with endothelial cells. Test hearts are attached to appropriate polymer tubing
whose tips are inserted into the blood reservoirs (maintained at 37oC) to complete the flow
circuit. Roller pumps control blood flow at a desired flow rate, and this is monitored noninvasively using an ultrasonic flow probe. The blood collected from a single animal is divided
into multiple blood reservoirs (as many as there are hearts to compare simultaneously).
Incomplete endothelialization may be detected via this in vitro assay, as long as contact of blood
from one animal with endothelial cells from another animal does not lead to immune-response
mediated thrombosis or other confounding adverse responses. Preliminary studies have shown
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that this method can distinguish differences between decellularized and freshly harvested porcine
hearts [26]. Additional experiments will be needed to test the thrombogenicity of hearts after
recellularization.
Studies can also be conducted with recalcified citrated blood flowing through the heart at
a lower flow rate (e.g., 1 L/min) for a shorter duration (e.g., < 30 min) to focus the assessment on
coagulation. Other studies can be conducted with heparinized blood flowing through the heart at
a higher flow rate (e.g., 3 L/min) for a longer duration (e.g., 2-3 h) to focus the assessment more
on platelet-mediated thrombosis. Assessment of plasma markers of complement activation,
platelet activation, and inflammation can also be conducted with human hearts and human blood.
While in vitro tests of thrombosis and associated markers are valuable tools, direct extrapolation
of in vitro results to the in vivo setting may not be possible, and the relevance of certain in vitro
tests is still being debated [120, 121].

1.9

DISCUSSION

One of the goals of tissue engineering research with decellularized whole organs is to
adapt the published protocols for decellularization of blood-contacting scaffolds for automation
and scaling to whole porcine hearts. Other goals include the development of strategies for
recellularization, growth factor delivery, bioreactor design, quality analysis, and measurement of
thrombogenicity in vitro prior to implantation. The possibility of using decellularized whole
porcine hearts combined with human cells to create viable hearts for transplant is getting closer
to reality [4]. Porcine hearts are similar to human hearts in size and anatomy, and the use of
porcine heart valves in humans has a long history of success [122]. The development of the
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decellularization process in rats [2, 29] has been successfully scaled to porcine hearts [21, 123].
Optimizing the decellularization process further will potentially limit damage to the ECM. Since
the ECM signals modulate inflammatory and reparative pathways, these signals affect cell
survival phenotype and also gene expression [124]. Expediting the decellularization process will
also reduce the risk of contamination and reduce the cost of reagents and labor. In reviewing the
literature, I found many papers that described decellularization methods, but very few that
described the optimization and automation of recellularization and decellularization strategies to
prevent thrombosis in whole organs.
This scope of this review chapter covered the progress that has been made to
decellularize whole hearts, including rodent, porcine and human hearts, since the first attempt
was reported in 2008 [2], as well as the methods for preventing thrombosis in medical devices.
Many variables have been studied for the process of decellularizing whole hearts, including
various detergents, concentrations, rinses or washes, flow rates, pressures, and times. This
review chapter highlights the most important parameters for optimization in future efforts to
automate decellularization and recellularization processes, and prevent thrombosis of bloodcontacting organs. I also described a method for the assessment of these strategies through the
use of an in vitro blood flow thrombogenicity assay [119].
In addition to the previous articles that have been reviewed in this chapter, much can be
learned from the history of decellularization of porcine heart valves and small intestine
submucosa (SIS), which have been approved as commercial products. Several review articles
have been written on these products. For example, Badylak et al. have reviewed the development
of SIS [33, 125-127] and also recently reviewed whole organ decellularization [125] and the use
of porcine bladder [128] for use as a matrix. Gilbert et al. [6] reviewed the decellularization
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process for tissues and organs, focusing primarily on the development of SIS. The use of
mechanical agitation, sonication and osmotic shock with hypertonic/hypotonic solutions were
discussed. SDS and Triton X-100 were proposed as detergents that could be used. A call was
made for the development of assays to determine the extent of decellularization.
Stem cells are a possible strategy for recellularization, since they are pluripotent, and may
be guided to differentiate into a variety of cell types. Use of iPSC has been proposed since they
could be patient-specific, but still have pluripotency. The efficiency of creating iPSC is
improving, and the use of environmental cues may eliminate the need for the viral introduction
of transcription factors [41, 42]. Transdifferentiation may be a better strategy than using iPSC,
since transdifferentiation may decrease the risk of teratoma formation associated with inducing
pluripotency. At the very least, the iPSC must be shown to be terminally differentiated prior to
implantation, as has been done by Advanced Cell Technology, Inc. (ACT), in a human clinical
trial using terminally differentiated human embryonic stem cells (hESC) for treating dry agerelated macular degeneration [129].
Although it was not the focus of this review chapter, other strategies have been proposed
for culturing cells into 3D structures without the use of decellularized scaffolds, mimicking
embryological development. Although the initial development of organs during embryonic
formation does not require the introduction of a separate scaffold, the size of these organs is very
small relative to an adult organ. The embryological organs create their own extracellular matrix
as they develop. As a child grows and matures into an adult, all of the organs constantly remodel
and replace the smaller versions with larger organs. This provides a rationale for growing new
hearts using neonatal or adolescent cells.
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The source of cells may be autologous or allogeneic. Ideally, the cells will be autologous,
but there may be situations in which autologous cells are not preferred. For example, one may
not want to use an elderly patient’s cells for recellularization, especially if they are diseased.
Even patient-specific stem cells may not be good candidates to recellularize a bioengineered
heart for transplantation in individuals with systemic disease. As cells age, they lose their
youthfulness, purportedly due to telomere shortening [130]. Juvenile cells that have many years
of life ahead of them could be a great source for recellularization. It may be preferable to grow a
heart with a younger patient’s cells, if they are properly immunologically matched. Cells could
be isolated from neonatal or young patients whose families agree to donate their organs. In the
best case, juvenile, autologous, patient-specific stem cells can potentially be used from tissue
banks, if the patient or the patient’s parents had the foresight to bank cells at a young age, or
retained the umbilical cord-derived stem cells at birth.
During recellularization, the coordination of multiple cell types in the matrix may require
extensive engineering of the matrix proteins. Suggestions of adding RGD peptides (a 3 amino
acid sequence from fibronection responsible for cell adhesion) to the matrix have been made
[93]; however, RGD peptides are not specific in attaching to the cells and can potentially bind to
thrombocytes as well. The use of other peptides such as YIGSR, which is a sequence from
laminin protein, may be more effective in not attracting the platelets and be more specific in
binding to the desired cell types such as endothelial cells.
There are numerous alternative strategies to the use of decellularized scaffolds and
patient specific cells for creating new hearts. For example, 3D printing using cells and ECM
proteins has been proposed as a possible method for engineering a new tissue. These
technologies hold the promise of exciting possibilities and are also worthy of additional research.
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In addition, cell sheet technology has been developed by Professor Okano’s lab [131] and
L’Heureux et al. [132] have described the use of cell layers rolled on a mandrel to create a blood
vessel.
Other organs have been decellularized and recellularized, including the trachea [133],
lungs [66, 134-140], liver [141, 142], pancreas [143], blood vessels [144], and kidneys [141,
145-148]. Many of these papers have outlined the design criteria for bioreactors for
decellularization and recellularization. The general principles addressed in this chapter pertaining
to the heart also apply to these other organs. Also, much can be learned from the processes used
for decellularization and recellularization studies of other organs that can be applied to the heart.
With all of these tissues, there is a need to prevent transmission of disease. Allografts
have been used for many years, and procedures are in place to decontaminate donated tissues,
including using acids and alcohols. Hodde et al. have described a method to evaluate tissues for
viral infection [149], the effects of sterilization on ECM composition and architecture [150], and
the effects of sterilization on ECM bioactivity and matrix interaction [151]. All of these
sterilization techniques will need to be adapted to decellularized whole organs.
The use of endothelial cells for recellularization is the ideal solution for preventing
thrombosis. In the case that there is not complete covering of the flow surface with endothelial
cells, a modified subendothelial surface would require the use of non-fouling molecules or
heparin molecules attached to the surface. However, this approach may prevent reendothelization
or alter the Vroman effect of protein adsorption to the surface, and great care must be taken if
these strategies are employed.
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The current status of this work is that hearts can be optimally decellularized, and success
has been obtained with attachment of cells to the scaffold, but full recellularization to provide
function while preventing thrombosis has not been achieved. Additional work is required to
automate and optimize the decellularization and the recellularization processes. Once the
processes for perfusion recellularization of the whole heart is optimized, other remaining issues
with the use of porcine hearts will need to be addressed, including the need for culturing large
quantities of immunologically-matched, patient-specific cells; the development of aseptic
protocols to maintain the organs free from contamination; re-innervation of the heart muscle;
shipping and storage protocols; and the development of surgical techniques to implant porcine
hearts into humans. It is my hope that these challenges may soon be overcome, and the promise
of regenerative medicine may be realized for heart failure patients.
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2

APPROACHES AND RESEARCH AIMS

2.1

SPECIFIC AIM 1

To design and create an automated, pressure-controlled process for optimal
decellularization of whole porcine hearts in order to improve reliability and replicability of the
results.
2.1.1

SUB-AIM

Reducing the total exposure time of SDS detergent solution required in an optimal
decellularization process from days to 6 hours and implementing hypotonic shocks to enhance
cell removal from the ECM.
2.1.2

RATIONALE

ECM consists of a large variety of components and using strong ionic detergents can
cause the decellularized tissue to be detrimental in tissue engineering due to the denaturation of
ECM component proteins. An automated system that allows for perfusion decellularization of
whole porcine hearts efficiently may improve the outcome.
2.1.3

HYPOTHESIS

Use of SDS as the main detergent solution in the decellularization process has shown
promising results in the literature. However SDS is an ionic detergent and can cause denaturation
of the ECM components. Creating an apparatus that can automatically control and increase the
pressure in the perfusion decellularization process may reduce the required time for optimal
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decellularization and especially reduce the necessary SDS concentration and exposure time. In
addition, the decellularization of whole porcine hearts will be more replicable by having a
computer control the process.
2.2

SPECIFIC AIM 2

To develop a reliable, inexpensive and quick method for measuring the cytotoxicity of
the created ECM using hemolysis of human blood.
2.2.1

SUB-AIM

Optimizing the decellularization process for reducing the cytotoxicity by minimizing the
required duration of after-wash with water or a nonionic surfactant solution.
2.2.2

RATIONALE

Cytotoxicity of the ECM created through the decellularization process is due to the
residual detergents that are detrimental in tissue engineering purposes. An established method for
measuring the cytotoxicity level is the use of a live\dead assay protocol on cells cultured with the
sample. However this method is time consuming and expensive. Through the hemolysis of
human blood, ruptured erythrocytes release hemoglobin that can be detected by absorbance in
the visible light bandwidth.
2.2.3

HYPOTHESIS

ECM samples can be incubated in a solution of human erythrocytes separated form blood.
The amount of hemoglobin release can be used as a marker for cytotoxicity of the samples. Various
after-wash procedures in the decellularization process will be implemented and the hemolysis assay
can be used to determine the optimal after-wash procedure that produces the lowest cytotoxicity in
the decellularized ECM.
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2.3

SPECIFIC AIM 3

To create beating slices of porcine cECM from whole decellularized porcine hearts with
the size of 1 cm2, combined with human cardiomyocytes.
2.3.1

SUB-AIM

To develop a protocol for differentiation of human iPSC into CMs and reseeding the cells
onto the porcine cECM.
2.3.2

RATIONALE

Human iPSCs are capable of proliferating indefinitely and can differentiate into cardiac
cells. Therefore they can be used to repopulate the cECM and create a human cardiac tissue that
can potentially be used for treatment of patients with heart disease. However, due to the
complexity and susceptibility of the iPSCs at their pluripotent stage, to date, no group has
reported creating beating porcine cECM with human iPSCs.
2.3.3

HYPOTHESIS

Slices of cECM can be made with accurately thicknesses using a cryostat. Human iPSCs
can be differentiated into CMs in a stage-wise manner and at the cardiac progenitor stage, the
cells can be reseeded onto the cECM and complete differentiation. Cardiac ECM may help the
arrangement and can act as a mechanical support of the cells. Due to the native composition of
the cECM, it may also aid in preserving the phenotype of differentiated CMs.
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3
3.1

Automation of Pressure Control for Whole Porcine Heart Decellularization
INTRODUCTION

Advances in technology, including total artificial heart transplantations, ventricular assist
devices [152, 153] and improved treatment techniques [154], have provided some improvement
in the treatment of heart disease, and slowed the accelerating need for end-stage organ
transplantation, yet alone are insufficient to meet the rising demand. The latest technologies,
including stem cell patches [155], 3D printing of tissues and whole organs [156], and tissue
engineering using extracellular matrix (ECM) derived biologic scaffolds are currently under
development.
The ECM consists of thousands of types of proteins, the concentration of each varying
between organs, and the mechanical properties of ECM change based on environment and age
[157]. In addition to providing a mechanical scaffold for homing and 3D functioning of the cells,
ECM serves as a signaling and communication material between the cells and promotes cell
proliferation and differentiation in the body [158]. Synthetic polymer scaffolds lack in advancing
complexity of vasculature and essential growth and differentiation factors [156]. The use of
decellularized tissue scaffolds has become an attractive solution as heart vasculature, mechanical
integrity, and biocompatibility are preserved while the magnitude of the immunogenic response
after transplantation is reduced if seeded with terminally differentiated autologous induced
pluripotent stem cells (iPSCs) [14, 159] The ECM provides an acellular structure capable of
being seeded by iPSCs or progenitor cells [59]. However, in recellularizing an organ, structural
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complexity raises issues of oxygenation and nourishing the seeded cells. The more tissues an
organ contains, the more structurally complex the organ becomes and that increases the difficulty
of effective diffusion throughout the entire vasculature [10]. Less complicated organs, such as
the trachea [133] or urinary bladder [160], have less such problems and are already capable of
recellularization. The heart provides a unique opportunity because retrograde perfusion through
the aorta can facilitate vascular perfusion [29].
Ideally, decellularization is a process in which the cellular components that promote a
chronic immune response, such as DNA and GAL epitopes are removed from the ECM, while
the ECM non-immunogenic matricellular proteins and growth factors are preserved [158]. A key
challenge in decellularization is to avoid chemical damage from overexposure of cell removal
reagents such as sodium dodecyl sulfate (SDS). Although SDS is considered one of the most
effective detergents for removing cells and immunogenic components from the ECM [2], excess
exposure creates a risk of removing glycosaminoglycans (GAGs) and growth factors as well as
denaturing ligands and proteins such as collagen, elastin and fibronectin within the structure [6,
161].
Automated systems assist in standardizing the decellularization process [162] and a
pressure controlled system can assure effective perfusion through the coronary vessels during the
decellularization process [31]. In this study, automated pressure control was used to optimize the
decellularization protocol with retrograde perfusion through the aorta in a porcine heart model.
Once hearts were decellularized into cardiac ECM (cECM), they were characterized chemically,
mechanically and the in-vitro thrombosis potential was investigated. The cECM was partially
recellularized using endothelial cells and human cardiac fibroblasts (HCF) to demonstrate the
recellularization potential. This work was published in Tissue Engineering Part C [194].
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3.2
3.2.1

MATERIALS AND METHODS
HARVESTING

Porcine hearts were harvested from slaughter-weight, 6-month-old, mature female
Hampshire, Yorkshire or Spot crossbreed swine at a local abattoir according to approved
protocols for safety and animal care. After exsanguination, the chest cavity was opened using a
12” Finochietto retractor and the heart was dissected from the lung while preserving as much of
the aorta, pulmonary artery, vein, and caudal and cranial vena cava as possible. Immediately
after removing the heart, a pressurized hand action pump filled with a solution of 1X phosphate
buffered saline (PBS), heparin (10 Units/mL) and 1X Antibiotic solution (100 U/mL penicillin,
100 µg/mL streptomycin, 25 µg/mL amphotericin B, Anti-Anti, Gibco®, Billings, MT), was
used to rinse all the chambers and vessels of the heart via antegrade perfusion through the vena
cava and pulmonary vein and retrograde perfusion through the aorta. Hearts were manually
massaged while being washed to remove any static blood in the coronary vessels to prevent
further thrombosis. The hearts were then transported in cold heparinized (10 units/mL) type 1
distilled water to the lab and frozen at -20°C.
3.2.2

DECELLULARIZATION APPARATUS DESIGN AND AUTOMATION

A Langendorff system based on Radnoti® porcine working heart system (Monrovia, CA)
was modified to be used as the decellularization apparatus. The modified apparatus contained a 5
L reservoir for the perfusate solution, a heat exchanger, a bubble trap and the main 5 L
decellularization chamber, with the heart submerged in the perfusate solution. A peristaltic pump
(Masterflex® HV-07557-00, Vernon Hills, IL) with Tygon L/S 36 tubing (Masterflex® E-3603)
was used to produce a pressurized pulsatile flow.
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A negative feed-back control system was implemented to maintain critical parameters
during the decellularization process. The system consisted of a computer running National
Instruments® (Austin, TX) LabView software and contained hardware to collect pressure data
while sending control signals to a pump. A proportional-integral-derivative (PID) control
algorithm monitored the pressure signal every tenth of a second and adjusted the pump signal to
maintain the desired pressure. The program also included functions for running timed
experiments, automatically adjusting pressure levels, and switching fluid streams via electrically
controlled solenoid valves, as well as a manual control mode. The pressure controller was
designed to control the pressure in the bubble trap. The pressure gauge was placed in line of the
flow system at the bubble trap, right before the flow entered the heart through the aorta.
A 10 L water bath with controlled temperature was used to maintain the temperature of
the decellularization process at a desired temperature (23 °C) by circulating the water through the
jackets of the reservoir and the main chamber, as well as the heat exchanger and the bubble trap.
Figure 3-1 shows the schematic of the apparatus design and the interface of the LabView
program. (The operating apparatus is shown in supplementary Videos 1 and 2, accessible online:
https://goo.gl/uX9wxA and https://goo.gl/pPqWua).
3.2.3

DECELLULARIZATION

Decellularization of porcine hearts was performed using SDS and Triton X-100 in the
decellularization apparatus. First, the hearts were thawed at 4°C overnight and removed from the
10 U/mL heparinized water. Excess fat was trimmed and the aorta was separated from the
pulmonary artery and cut perpendicularly at the brachiocephalic trunk. The aorta was then
cannulated with a Radnoti® (Monrovia, CA) ½” male tube and connected to the apparatus. The
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heart was submerged in the 1X PBS solution to avoid axial stress on the aorta due to the heart’s
weight.

Figure 3-1. Automated controller interface (left) and schematic view of the automated
pressure controlled bioreactor for porcine heart decellularization (right). 1: solution
reservoir; 2: peristaltic pump; 3: heat exchanger; 4: bubble trap; 5: decellularization
chamber; 6: temperature-controlled water bath; 7: control loop.
Care was taken while connecting the heart to attach the connector away from the aortic
valve to ensure that the coronary orifices were not covered and the valve could work properly.
The decellularization process then started with perfusing 1X PBS through the coronary vessels to
remove the blood and thromboemboli followed by an hour of non-recycled perfusion of type 1
distilled water. Alternating between PBS and distilled water resulted in a hypotonic shock to the
cells, facilitating decellularization. During the 1 h of PBS perfusion, the pressure was gradually
increased to 4 psi using the automated system and distilled water perfusion was performed at 5
51

psi. The perfusion continued with 3 recirculating 10 L batches of 0.5% (w/v) SDS in distilled
water for 2 h, followed by 2 h of non-recirculating distilled water, all performed at controlled
pressure of 5 psi. The sixth hour of SDS exposure was followed by 2 h of non-recirculating
distilled water at 5 psi and 12 h of overnight perfusion of 10 L recirculating distilled water at 3
psi. The water was then replaced with 10 L 1% (v/v) Triton X-100 and perfusion was conducted
while automatically increasing pressure to 5 psi for 2 h to remove remaining SDS and cellular
debris. Decellularization was finished with an extensive wash of the heart with distilled water at
5 psi for at least 5 h. The decellularized heart was then dissected and random samples from the
left and right atria, ventricles and septum wall were selected for characterization. Samples from
the left ventricle were isolated for recellularization or the heart was preserved intact for vascular
corrosion casting which is a technique for obtaining the surface area and volume of vasculature
in the heart.
3.2.4

DNA, COLLAGEN AND GLYCOSAMINOGLYCANS MEASUREMENTS

To measure the amount of residual DNA fragments, samples were taken from left and
right ventricles, left and right atria, and the septa of decellularized and native hearts. Samples
were sterilized by immersion in 1X Antibiotic solution in 70% ethyl alcohol for two hours
followed by submersion in cell growth medium (DMEM/F-12 with 10% FBS [fetal bovine
serum, Gibco®], 100 U/mL penicillin and 100 µg/mL streptomycin [Gibco®]) for 48 h. The
samples were then lyophilized and weighed. DNA was extracted from approximately 5 mg of
dry samples using Qiagen® DNeasy Blood and Tissue Kit (Valencia, CA). The samples were
solubilized with proteinase K overnight and after several centrifugation steps and washing with
different buffers, DNA extracts were prepared for quantification. Quant-iT PicoGreen
(Invitrogen Corp., Carlsbad, CA) reagent was added to each sample. Samples were excited at
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485 nm and fluorescence intensity was measured at 520 nm using a Synergy 2® Multi-Mode
Microplate Reader. Gel electrophoresis was performed with DNA extracts loaded on 1% agarose
gels to characterize the residual DNA in the structure of the ECM.
To examine the collagen and sulfated glycosaminoglycans (sGAGs) content of the
cECM, Sircol® Soluble Collagen Assay Kit (Biocolor Ltd., Newtownabbey, UK) and a
Blyscan® sGAG Assay Kit (Biocolor, Ltd), were used, respectively. Approximately 3 mg of dry
cECM samples were digested over 3 days using an acid/pepsin solution at 4°C and Sircol® Dye
Reagent was added to each sample to form a collagen-dye complex based on the manufacturer’s
instructions. After solubilizing the dye-reagent complex with an alkali reagent, the absorbance of
samples at 555 nm was measured. For sGAGs measurements, each sample was completely
solubilized in papain extraction solution for 3 h at 65°C and Blyscan® dye reagent was added to
all samples to precipitate the sGAGs-dye complex. The dissociation reagent was then added to
dissolve the complex and absorbance was measured at 659 nm.
3.2.5

CELL CULTURE

Murine endothelial cells (MS-1 cell line) labeled with green fluorescent protein (GFP)
were thawed and cultured in cell growth medium (DMEM/F-12 with 10% FBS [fetal bovine
serum, Gibco®], 100 U/mL penicillin and 100 µg/mL streptomycin [Gibco®]). Human cardiac
fibroblast (HCF) cells were cultured in Cardiac Fibroblast Growth Medium (Cell Applications
Inc., San Diego, CA). MS-1 and HCF cultures were maintained at 37°C and 5% CO2 and were
both used at early passages. A FLoid® cell imaging station was used to visualize and measure
the confluency of the cells as well as for image acquisition.
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3.2.6

MACROPHAGE STIMULATION ASSAY

The immunogenic potential of the cECM was measured and compared to fresh heart
samples by quantifying the amount of nitric oxide (NO) generated by macrophage cells in
contact with specimens. Mouse leukemic monocyte-macrophages (cell line RAW 264.7, SigmaAldrich®, St.Louis, MO) were cultured with 3 mL of cell growth medium (10% FBS, DMEM
with no phenol red) in 6-well plates until 70% confluent. Lyophilized samples of decellularized
(n=6) and native (n=6) hearts were ground to a fine powder using a pestle and mortar filled with
liquid nitrogen. Fourteen mg of each specimen were added to a well of 6-well plates. In order to
ensure the production of NO by stimulated macrophages, powdered lyophilized E. coli bacterial
extract was added to wells as positive controls and wells without extract served as negative
controls. After 24 h of incubation at 37°C, 5% CO2, all media were centrifuged at 15,000 g and
the amount of NO in the supernatant was quantified as the free stable nitrite form (NO2-) using
Griess Reagent Kit (Life Technology®, Grand Island, NY) according to the manufacturer’s
instructions. The concentration of nitrite in the media was then interpolated from a nitrite
standard reference curve (0 to 100 µM).
3.2.7

VASCULAR CORROSION CASTING

Corrosion casting was performed on native and decellularized porcine hearts to ensure
the integrity of the coronary vessels after decellularization. Two hearts were prepared for casting
by surgically suturing the aortic valve closed and placing two 2.5 cm (1") diameter and 1.6 mm
(1/16") thick N45 neodymium magnets on either side of the aortic valve. Magnets were
positioned carefully not to block the coronary orifices. The aortas were then cannulated with a
Radnoti® ½” male tube and connected to a peristaltic pump. A solution of ice cold 2X PBS dyed
with trypan blue was slowly pumped into the heart to ensure perfusion through the coronary
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vasculature and to hypertonically shrink the native endothelial cells in order to enhance
perfusion. Ice cold polyurethane and an epoxy casting resin containing a catalyst (Dowagiac®,
Specialty Resin & Chemical LLC, MI) were then mixed at a 35:65 ratio, and immediately
perfused through the heart for 5 min. The tubes were then detached and the hearts were allowed
to be incubated at room temperature for 1 h to ensure curing was complete. Hearts were then
immersed in 3.5 L of 15% NaOH at 37°C to digest the organic tissue. The NaOH solutions were
renewed every 3 days or when the solutions became cloudy due to being saturated with the
digested tissues. After 10 days, the heart tissues were fully digested and the polymer casts of the
internal coronary vasculature were visible. The hearts were placed in 1x PBS overnight, then
residual tissue was manually removed.
3.2.8

HISTOLOGY AND SCANNING ELECTRON MICROSCOPY

Decellularized, native, and re-endothelialized cardiac samples from left and right
ventricles and atria and the septum wall were dissected and fixed overnight in a solution of 4%
paraformaldehyde (PFA; Sigma- Aldrich®) in 1X PBS. The samples were then dehydrated using
30%, 50%, 70%, 95% and 100% ethanol. Afterward, samples were immersed in xylene and
embedded in paraffin. Using a microtome, 5 μm slices were made and placed on Fisherbrand®
(Pittsburgh, PA) microscope slides. Sectioned samples were then deparaffinized and stained
according to the manufacturer’s instructions with hematoxylin and eosin (Thermo Scientific®,
Pittsburgh, PA), Orcein (O7380; Sigma, St. Louis, MO), or Picro-sirius red (Direct Red 80,
#365548, Sigma-Aldrich, Saint Louis, MO) to examine the cellular components, elastin, and
general collagen in the native and decellularized samples. Images were acquired using an
EVOS® FL Cell Imaging System (Life Technology®, Grand Island, NY).
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Scanning electron microscopy (SEM) was performed on decellularized and native heart
samples for surface characterization. Specimens were prepared for high vacuum microscopy by
fixation in 2% glutaraldehyde in 1X PBS for 24 h at 4°C, dehydration in acetone, and
crosslinked with OsO4. Samples were then dried in a CO2 critical drier and coated with a 3 nm
layer of platinum to enhance conductivity. A Phillips®/FEI XL30 ESEM™ FEG (Hillsboro, OR)
Environmental Scanning Electron Microscope was used to acquire images with a field emission
gun (FEG) electronic beam at high vacuum.
3.2.9

MECHANICAL PROPERTIES ASSAY

Elastic moduli of the decellularized and native heart samples were calculated by
measuring the compression stress as a function of strain in order to evaluate the mechanical
stiffness of the decellularized heart samples compared to native hearts kept in PBS at 4 °C for
24h after harvesting. Square shaped, wet samples, approximately 10 mm × 10 mm and 5 mm
thick, were longitudinally dissected from the septum and left and right atrium and ventricle
walls. An Instron® 3342 Single Column Universal Testing System (Instron, Norwood, MA) was
used to perform compression tests. Tissue samples at room temperature were placed flat on the
lower metal plate and compressed at a constant rate of 0.07 mm/s until a compressive force of
45N was achieved. Plots of stress vs strain for the specimens were created and the elastic moduli
were calculated at the linear portions of the stress/strain curves.
3.2.10 CYTOTOXICITY ASSAY

MS-1 endothelial cells were used to assess cytotoxicity of the decellularized hearts to
ensure that the cECM did not adversely affect cell viability. One cm2 samples were dissected
randomly from the endocardium of the left ventricular walls of decellularized porcine hearts and
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sterilized by immersion in a solution of 1X Antibiotic solution in 70% ethyl alcohol overnight.
Samples were then soaked twice in 1X PBS and incubated in cell growth medium at 37°C, 5%
CO2 for 48 h. Samples of cECM (n=9) in 3 ml of cell growth medium were then placed in wells
of 6-well plates, while wells without cECM samples served as controls. MS-1 endothelial cells
(1×105) were detached from culture flasks using 0.05% Trypsin-EDTA and seeded onto each of
the cECM samples and control wells. Cells were labeled with 2 µM calcein AM and 4 µM EthDIII (Biotium® Viability/Cytotoxicity Assay, Hayward, CA) to examine the health and viability of
the cells in samples with and without cECM after 1 day and 3 days of culture.
3.2.11 SLICE RECELLULARIZATION

To recellularize cECM samples, MS-1 and HCF cells were labeled with Vybrant® DiO
and DiI lipophilic tracers (Life Technologies®, Grand Island, NY), respectively. Labeling was
performed by incubating 70% confluent cell layers in T-75 culture flasks with 5 ml of serum-free
media and 25 μL of the supplied dye labeling solution at 37°C for 20 minutes. Cells were then
detached using Trypsin/EDTA, centrifuged and slowly dispensed, at a concentration of 104
cells/mL, onto 8 mm diameter round, 1 mm thickness cECM samples (n=12) placed in 48 well
plates. One mL of medium was renewed every two days. Representative fluorescence images
were acquired after 1 week of culture and recellularized samples were fixed in 4% PFA for
histology imaging.
3.2.12 PERFUSION RECELLULARIZATION OF RIGHT VENTRICLES

Decellularized right ventricle of the hearts were dissected and trimmed. The sections
were then cannulated through the right coronary artery and large open arteries were ligated using
a tissue adhesive (3M™ Vetbond, St. Paul, MN). Tissues were then placed in the perfusion
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bioreactor and decontaminated by perfusing sterilization solution for 4 hours followed by
multiple rinsing and perfusion of sterile 1X PBS to thoroughly remove the sterilization solution.
Decellularized right ventricles were perfused with 10 mL/min of growth medium, submerged in
500 mL in a perfusion bioreactor, incubated at 37°C, 5% CO2 for 24 hours. One hundred million
(108) human umbilical vein endothelial cells (HUVECs) labeled with DIO (green) were perfused
into the cECM at a concentration of 106 cells/mL and the growth medium perfusion was started
after a 4 hour interval to let the cells attach to the cECM. After 10 days the tissue was removed
from the bioreactor and 5×107 HCFs labeled with DID (red) were needle-injected into ten
different areas of the myocardium. The growth medium was renewed and 10 mL/min perfusion
of growth medium was restarted 4 hours after injection.
3.2.13 THROMBOSIS ASSAY

A static blood thrombosis assay was developed to qualitatively examine the
thrombogenicity of porcine hearts in vitro. Bovine blood was collected at a local abattoir by
cannulating the aorta of the heart immediately after slaughter using an 18” long, 1” diameter
cannula and collecting the blood in 1 L flasks containing 1500 units of sodium heparin as
described by Zhang et al. [163].
To develop the assay, in addition to the porcine hearts, 3 bovine hearts were
decellularized by aortic perfusion of 10 L of 0.5% SDS for 7 days with renewing the solution
every day followed by rinsing with type 1 distilled water after the process. Freshly obtained
blood was then perfused through coronary arteries until the chambers of the bovine and porcine
heart were filled; the heart vessels were then clamped and the hearts were immersed in a
container of blood for 4 h. Native bovine and porcine hearts were used as controls and similarly
perfused. After 4 h the hearts were thoroughly rinsed with 1X PBS through all chambers and the
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aorta. To evaluate thrombosis, blood clots that could be rinsed out of the heart chambers and
vessels were examined visually and the hearts were dissected open to assess platelet adherence to
the chamber walls.
3.2.14 STATISTICAL ANALYSIS

Data are shown as average ± standard deviation and the sample size for all of the
quantification experiments was n=5 unless stated otherwise. SAS® JMP® 11 (Cary, NC)
software was used for statistical analysis of the data. For examining the significance of
comparisons, α=0.05 was considered as the significance level of p-values. Student’s t-test was
used for analyzing the data in two groups and the Tukey-Kramer test was performed on the data
with multiple groups.
Because of the change in density of the heart after decellularization, the data for
quantities of sGAGs and collagen in cECM samples were normalized and reported using the dry
mass of the native hearts as the base. For the normalization, the overall weight loss of each of the
compartments (right and left atria, ventricular walls, and septum wall) was determined by
measuring the ratio of water content to the mass of lyophilized samples in both cECM and native
groups and calculating their fraction. The standard deviations of the reported quantities of
sGAGs and collagen in cECM samples were determined considering the standard deviations of
initial non-normalized values and decellularization weight loss of dried samples.
3.3
3.3.1

RESULTS
WHOLE HEART DECELLULARIZATION

A total of 20 excised porcine hearts were used in these studies, 10 untreated hearts were
used as negative controls for various experiments, and 10 hearts were decellularized using the
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controlled pressure system (Figure 3-1) with 6 h of ionic detergent wash (SDS) and 2 h of nonionic detergent (TX-100). Isotonic and hypotonic shocks with PBS and type 1 distilled water,
respectively, before and in between steps of the decellularization process, improved the quality
of the decellularization and decreased the total decellularization time and detergent exposure. It
was observed that the required flow rate to achieve the set point pressure during the SDS
perfusion increased from 850 mL/min to 2250 mL/min which is due to cell removal and
expansion of the coronary vessels. Figure 3-2 shows a representative porcine heart before (A)
and 24 h after decellularization (B). The remaining extracellular matrix was white or translucent
due to the disappearance of the red coloration caused by blood and myoglobin proteins. The
heart’s shape was preserved and the heart valves remained intact and functional. At the time of
harvesting, most of the hearts were soft and flexible. At the beginning of decellularization, when
they were transferred from the refrigerator to the apparatus, the hearts were rigid and inflexible,
which helped the decellularization process by keeping the aortic valve closed, directing the
perfusion through coronary artery orifices. During decellularization the cECM became soft and
flexible again.
In the H&E staining (Figure 3-2.C,D), the cell cytoplasm was stained with eosin Y (pink
color) and the cell nuclei stained with hematoxylin (blue color). The decellularization process
removed the cells and cellular components. Sirius general collagen stain (Figure 3-2.E,F) stained
collagen protein fibers red, cell cytoplasm yellow, and nuclei black. Comparing the
representative images from these different sections of the heart before and after decellularization,
the process removed cells and cellular components while the collagen matrix was kept intact.
Elastin protein fibers were visualized using Orcein stain represented by the dark brown color as
shown in Figure 3-2.G,H.
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3.3.2

DNA

DNA can initiate an immune response if it enters a foreign body. However, in addition to
DNA, GAL epitope and other membrane proteins and epitopes have been shown to cause an
acute immune response that can lead to rejection of a transplanted organ [33]. Since DNA is in
the nuclei of the cells, it can be used as a marker for cell removal and decellularization efficacy
[35]. Samples of cECM (n=5) from 5 different sections (right and left atria, ventricular walls, and
septum wall) of 3 decellularized hearts were prepared for recellularization by sterilization and
incubation in cell growth media which contains DNAses that are known to digest residual DNA
[15].
The DNA content was extracted using Qiagen™ DNeasy® kit, fluorescent-stained with
Quant-iT™ PicoGreen® and the fluorescence was measured. As shown in Figure 3-3.A, the
amounts of residual DNA varied in different portions of the heart after decellularization. Samples
from the right atrium and left atrium exhibited the highest and lowest DNA removal values (with
averages of 99% and 97%, respectively) from 5 different portions of the heart. P-values of less
than 0.0001 suggest strong statistical evidence for DNA removal from all portions of the heart
after automated, pressure controlled decellularization.
The number of DNA base pairs (bp) in left ventricle samples of native and decellularized
hearts was determined via gel electrophoresis. It has been suggested that DNA larger than 200 bp
remaining in decellularized ECM can cause a chronic immune response [8]. As shown in
Figure 3-3.B, no DNA with more than 200 bp length in cECM samples was detected, while a
wide range of DNA sizes was observed in the native heart samples.
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Figure 3-2. A representative porcine heart before (A) and after (B) automated pressure
controlled decellularization. Hematoxylin and eosin stained histological images of native
(C) and decellularized (D) left ventricular wall samples illustrate complete cell removal.
Sirius stained histological images for total collagen in native (E) and decellularized (F)
samples illustrate cell removal as well as collagen (red) preservation. Orcein stained
histological images for elastin in native (G) and decellularized (H) samples illustrate elastin
protein (dark brown) preservation. Scale bars represent 20 mm (A, B) and 100 µm (C-H).
10X magnification lens was used for histology imaging (C-H).
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3.3.3

MACROPHAGE STIMULATION

Macrophages are white blood cells that can contribute to stimulating the immune system
by encouraging inflammation (M1 phenotype, killer), or moderating the immune response and
promoting tissue repair (M2 phenotype, healer). Killer macrophages secrete nitric oxide as they
stimulate the immune system [164, 165]. The level of stimulation can be determined by
measuring the concentration of produced nitric oxide [22]. The amount of nitric oxide produced
by stimulated macrophage cells was quantified as stable nitrite in the medium using Griess
Reagent® Kit for decellularized (n=6) and native (n=6) left ventricular samples in the presence
of positive and negative controls. As shown in Figure 3-3.C, the concentration of nitrite (µM)
formed in the media by macrophage cells exposed to either the negative control or stimulated
with decellularized specimens did not produce statistically significant differences (pvalue=0.80), while the native and decellularized groups had a 7.27 µM difference in their
average of secreted nitrite with high statistical significance (p-value <0.0001). The positive
controls showed the highest capacity of nitrite production by the macrophage cells (80.35 µM).
3.3.4

GLYCOSAMINOGLYCAN (GAGS)

In order to characterize cECM and examine the effects of automated, pressure controlled
decellularization on the GAGs content of the hearts, 5 random biopsies were obtained from
different sections (right and left atria, ventricular walls, and septum wall) of 3 decellularized
hearts. Sulfated GAGs were quantified using Blyscan® sGAGs Assay and the normalized results
are shown in Figure 3-4.A. Comparing the average amounts of sGAGs between the native and
decellularized samples, it was observed that the amounts of sGAGs were not significantly
different in various sections of the native heart samples except in the right atrium which had the
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highest quantity of sGAGs; however, a statistically significant difference was observed between
all groups of cECM samples except the right atrium, right ventricle and septum.

Figure 3-3. (A) DNA content in different sections of the native and decellularized hearts.
(B) Size of the DNA fragments in native and decellularized tissue samples measured using
agarose gel electrophoresis. (C) Concentration of nitrite in the macrophage cell media as an
indicator for stimulation level. Fine powder of lyophilized native and decellularized hearts
were added at equal amounts to the wells of 70% confluent macrophages. Lyophilized
Escherichia coli bacterial extract was added to wells as positive controls and wells without
extract served as negative controls. LA: left atrium; LV: left ventricle wall; RA: right
atrium; RV: right ventricle wall; Sep: septum wall; NS: no significant statistical difference;
*: p < 0.05.
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The highest amount of sGAGs in cECM was in samples from the left atrium, with an
average of 40 µg/mg (normalized to weight of lyophilized native tissue) and the lowest was
found in the right ventricle samples. The ratio of GAGs in cECM to native samples was 0.17 and
0.18 and 0.32 for right atrium, right ventricle and septum, respectively, while there was no
statistically significant deference between cECM and native samples in left atrium and ventricle.
3.3.5

COLLAGEN QUANTIFICATION USING SIRCOL® ASSAY

The amount of soluble collagen was measured in decellularized (n=5) and native (n=5)
sample biopsies from different sections of 3 decellularized hearts using Sircol® Soluble Collagen
Assay Kit. The normalized amounts of soluble collagen in different sections of the native and
decellularized hearts (Figure 3-4.B) showed a decrease in the amount of collagen in the right
ventricle, septum, left atrium and left ventricle after decellularization. No statistical significant
(p>0.05) difference was observed in the right atrium between the decellularized and native
hearts. Although not statistically significant in all groups, collagen preservation tended to be
higher in the right portion of the heart than the left heart.
3.3.6

VASCULAR CORROSION CASTING AND SEM IMAGING

Casts of the vascular network of native and automated pressure controlled decellularized
porcine hearts are shown in Figure 3-5.A,B respectively. The casts were created by retrograde
perfusion of polyurethane resin and catalyst through the coronary blood vessels, curing the
polymer, and then digesting the heart tissue with NaOH. The resulting cast produced a 3D model
of the vascular network that could be used for visual examination of the coronary blood vessels.
Care was used when handling the casting during and after processing since the hardened resin
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was brittle and the structures contained microvessels. As shown in Figure 3-5.B, the vasculature
of the cECM was preserved during the decellularization process.

Figure 3-4. (A) Sulfated GAGs content in different sections of the native and decellularized
hearts. (B) Soluble collagen content in different sections of the native and decellularized
hearts. *: statistical significant difference (p<0.05)
SEM imaging was used for microstructural analysis of the cECM and comparison with
the native tissue. As shown in Figure 3-5.C-F, the decellularization process increased the
porosity of the tissue by removing the cellular components but preserved the protein fibril
network. The structure of the cECM was observed to be similar to the native heart samples in
both left atrium (Figure 3-5.C,D) and left ventricle (Figure 3-5.E,F) and the coronary blood
vessels remained intact.
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3.3.7

MECHANICAL PROPERTIES

Young’s elastic modulus was determined by plotting compression stress as a function of
strain in decellularized and native heart samples and finding the slope of the graph at linear
portions at both low and high strains. The results are shown in Figure 3-6.A,B. While the results
were not statistically significant in the right and left atria, applying relatively small amounts of
pressure tended to result in more deformation in the cECM samples than native hearts (Figure 36.A) in all groups. This may be because during decellularization the ECM remained the same
relative size as the cellular debris was removed, therefore it became more hollow and easier to
deform. Consequently the cECM samples tended to have a smaller Young’s elastic modulus than
native hearts.
As shown in Figure 3-6.C-G, native samples reached the ultimate resistance force of 45N
earlier at lower strain than decellularized cECM samples. Although the elastic moduli
demonstrated a more accelerated increase in the native samples, cECM samples showed higher
elastic moduli (Figure 3-6.B) under high pressure. This observation might have been caused by
not taking into account the Poisson’s ratio and assuming the same 1 cm2 area for the compressed
samples which overestimates the pressure at high strains.
3.3.8

MYOCARDIUM SLICE RECELLULARIZATION AND CYTOTOXICITY
ASSESSMENT

Culture of MS-1 cells on tissue culture plastic and in the presence of cECM followed by a
Live/Dead assay showed no indication of the cECM causing cytotoxicity. Cells seeded with and
without cECM reached full confluency in a similar time frame (3 days) and the quantities of
healthy and deceased cells were similar in both control and cECM groups (Figure 3-7.A-D).
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These results confirmed that MS-1 endothelial cells were able to proliferate in the presence of
cECM with comparable results to traditional cell culture conditions.

Figure 3-5. Polyurethane vasculature cast of native (A) and automated pressure controlled
decellularized (B) hearts. The tissue was digested in 15% NaOH at 37 °C. Arrows point to
the preserved microvasculature. SEM images of native (C) and decellularized (D) left
atrium and native (E) and decellularized (F) left ventricle illustrate intact blood vessels and
porous fibril network after decellularization.
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Figure 3-6. Elastic moduli of decellularized and native samples from different section of the
heart at low (A) and high (B) strains. Young’s modulus was measured by compression tests
on an Instron® system up to compressive force of 45N and calculating the tangent line of
the stress versus strain at various strains. Stress versus strain results of compression tests
for (C) left ventricle, (D) left atrium, (E) septum, (F) right ventricle and (G) right atrium.
3.3.9

RIGHT VENTRICLE RECELLULARIZATION

Polyurethane casts of both decellularized and native porcine hearts were created in order
to identify an area in the decellularized heart with an appropriate coronary vessel diameter for
cannulation and to map the vasculature network in the decellularized myocardium. These casts
(Figure 3-5.A,B) demonstrate that the integrity of blood vessels was preserved after
decellularization and were also used for selection of the area for recellularization.
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Figure 3-7. (A-D) Cytotoxicity examination of automated pressure controlled decellularized
cECM. Viability of the MS1 cells in wells without cECM (A,C) and in wells with cECM (B,
D) after 1 day (A,B), and 3 days (C, D) of cell culture was tested with Biotium®
Viability/Cytotoxicity assay. (E-H) Representative images of recellularization with HCF
and MS1 cells. Fluorescence (E) and H&E stained histological images (F) acquired from
DiI labeled HCF seeded on left ventricle myocardium cECM after 7 days of culture.
Fluorescence (G) and H&E stained histological images (H) acquired from DiO and GFP
labeled MS1 cells seeded on left ventricle endocardium cECM after 7 days of culture. Scale
bars represent 100 µm.
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The perfusion bioreactors were designed with filters for ventilating the chamber and
separate input and outputs for changing the liquid medium and perfusing the tissue (Figure 38.A). Separated right ventricle of the hearts were cannulated through the right coronary artery
and ligated at the points shown by the red arrows in Figure 3-8.B. Right ventricles were
decontaminated (Figure 3-8.C) and recellularized with HUVECs and HCF cells (Figure 3-8.D).
After 14 days of recellularization with HCF cells, the tissues were fixed in 4% formaldehyde for
24 hours. Biopsies were taken from random areas of the recellularized tissue and a confocal laser
microscope was used in order to acquire 3D images. As shown in Figure 3-8.E-G, HUVECs
(green) have attached to the lumen of the blood vessels. Injected fibroblasts created high density
clusters around the points of injection and as shown in the images, they demonstrate lower
dispersion through the cECM compared to the HUVECs.
3.3.10 THROMBOSIS ASSESSMENT

In vitro static blood thrombosis assays were performed using 1.5 U/mL heparinized fresh
bovine blood on native and decellularized porcine and bovine hearts to assure that the crossspecies properties of blood and cECM did not interfere with the experimental results. After 4 h
of static blood exposure, the hearts were perfused with a 1X PBS solution. Blood clots emerged
from the coronary sinus and venous sections of the decellularized hearts, but not from the native
hearts. All of the hearts were then dissected and the adherence of platelets to the coronary vessels
and inner walls of the heart was visually analyzed as described by Sukavaneshvar et al. [166].
Although, no clot formation was observed in any parts of the native hearts (Figure 3-9.A,C,E and
G), the coronary sinuses and arteries of the decellularized hearts were clogged with blood clots.
Platelets adhered to the inner walls of the right and left portions of the decellularized porcine and
bovine hearts as shown in Figure 3-9.B,D,F and H.
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Figure 3-8. Perfusion recellularization bioreactor (A). Dissected right ventricle (B) from the
decellularized heart. Arrows show ligated vessels using tissue adhesive. Decontamination of
a right ventricle attached to the bioreactor (C). Cannulated decellularized right ventricles
in the perfusion bioreactor placed inside an incubator (D) and representative 3D images of
recellularized right ventricles, 24 days after HUVECs (Green) perfusion and 14 days after
HCFs (Red) were directly injected into the myocardium (E-G). Note the higher distribution
of endothelial cells along the vasculature versus the HCFs that are localized to the injected
region (E,F) and HUVECs covering the walls of a large (1 mm diameter) branch of the
right coronary artery (G).
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As shown in Figure 3-9.F and H, significant thrombosis occurred inside the left and right
portions of the decellularized bovine hearts and the non-adherent clots had to be removed for
visual observation of the platelet adherence to the decellularized tissues.

Figure 3-9. Thrombosis assay results on porcine (A-D) and bovine (E-H) hearts. Native
hearts did not exhibit thrombogenicity in neither the right (A, E) nor the left (C, G)
portions, while activated platelets and thrombosis was observed in the right (B, F) and left
(D, H) portions of the decellularized hearts. Arrows point at activated platelets adhered to
the ventricular walls (B, D) and circles emphasize on blood clots formed in the ventricle
and atrium of the decellularized hearts.
3.4

DISCUSSION

Decellularization of whole porcine hearts was accomplished with 6 h SDS and 2 h Triton
X-100 washes. When compared to previous studies, this process included less detergent exposure
while preserving the chemical and mechanical integrity of the ECM [2, 3, 29]. It has previously
been shown that detergents affect the basement membranes of biologic scaffolds and SDS has
the most destructive effect among various ionic and non-ionic detergents [161]. However, to
remove cellular material and avoid inflammatory response at the time of transplantation, the use
of SDS seems to be an essential step to strip the ECM of any cellular components [3, 167].
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Therefore, it was decided to use SDS in an optimized manner to preserve the vital components of
the ECM while removing immunogenic cellular materials, resulting in more fully decellularized
hearts without the potential for an immunogenic response due to residual cell debris.
DNA content can be used to determine the efficiency of the decellularization process in
terms of removing cells and immunogenic factors [35]. It is important to note that the reported
amounts of DNA in native tissues varies greatly in the literature, as shown in Table 3-1, which
requires reporting the percentage of DNA removal as well as residual DNA content after
processing. In this study, more than 98% of DNA was removed using an automated pressure
controlled process.
Collagen is responsible for mechanical properties and acts as a signaling molecule for
cell differentiation and proliferation [168]. Amongst the various components of the ECM,
collagen is the most abundant, with more than 20 types. In a previous study, Naugle et al.
showed that type VI collagen induced myofibroblast differentiation and type I and III collagen
improved proliferation of cardiac fibroblasts [169]. By both collagen quantification (Figure
3-4.C,D) and general collagen staining (Figure 3-2.E,F), our decellularization results
demonstrated that collagen was highly preserved.
GAGs are another fundamental component of the ECM that needs to be preserved. GAGs
bind growth factors and keep water within the structure of the ECM [168]. It has also been
demonstrated that GAGs are susceptible to damage by detergents [19] and dissociating enzymes
[170]. Less SDS exposure from our decellularization method increased the preservation of GAGs
within the structure of the ECM compared to a previous study [21].

74

Table 3-1. Summary of DNA content in various perfusion decellularization methods for
hearts.
Porcine heart

Native
ng/mg
8.2

Decellularized
ng/mg
0.82

Samples
Criteria
dry

Porcine heart

8.5

0.66

Porcine heart

397

Rat heart

Tissue

DNA Removed (%)

Reference

90.0

[25]

dry

92.2

[21]

35

dry

91.2

[23]

510

16.6

wet

96.8

[2]

Human heart

630

24

wet

96.2

[29]

Porcine heart

691

10

dry

98.5

Figure 3-3.A

Porcine kidney

1,000

13

dry

98.7

[148]

Mouse heart

1,100

33

dry

97.0

[20]

HUV

5,000

100

dry

98.0

[15]

Rat heart

404,000

2400

dry

99.4

[17]

Mechanical properties of the heart, as a continuously beating organ, are crucial for proper
function. Maintaining the mechanical strength and stiffness of the cardiac ECM is one of the end
goals of whole heart decellularization. However, the stiffness of the ECM can also dictate
differentiation of stem cells [171, 172]. Pek et al. showed ECMs with elastic moduli ranging
from 0.1 kPa to 34 kPa changed the differentiation of mesenchymal stem cells from a neural
phenotype to an osteogenic phenotype [173]. Previous decellularization reports of rat [2, 174]
and porcine [175-177] hearts demonstrated an increase in the stiffness (i.e. elastic modulus) of
decellularized scaffolds compared to their native controls from tensile tests that stretched the
scaffolds in various directions. This increase in the stiffness was believed to be due to the denser
and more compact matrix that is a result of decellularization [176]. In our study compression
tests were performed and it was shown that at low compression strains native tissues
demonstrated higher stiffness; however, under high compression strains elastic moduli of the
cECM samples were higher or equal to the native hearts, which is similar to previous reports.
It is known that decellularized porcine heart valve matrices induce human platelet
activation and cause thrombosis and inflammatory problems [90]. In our work, whole
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decellularized porcine and bovine hearts were shown to induce platelet activation and adhesion
while native hearts were found to be highly resistant to thrombus formation (Figure 8). This is
likely due to the presence of the endothelial cell layer on the inner surface of the endocardium.
As previously described by Robertson et al. [3] re-endothelialization of the decellularized rat
heart with rat neonatal cardiomyocytes diminished the thrombogenicity of the scaffolds in-vitro
and in-vivo as well as increasing the beating function of recellularized hearts. Therefore,
recellularization with endothelial cells attached to the blood contacting surfaces of the ECM is
crucial for whole organ engineering and further studies need to be performed to reduce the
thrombosis and inflammatory stimulation of decellularized organs.
The use of decelluarized organs has been proposed by several groups for whole organ
engineering. For example, in 2008, Ott et al. succeeded to create functional beating rat hearts by
decellularization of native hearts with 12 h retrograde perfusion of 1% SDS and recellularization
with neonatal cardiomyocytes and endothelial cells [2]. A report on recellularization of
decellularized mouse hearts with human iPSCs by Lu et al. [20] included a modified retrograde
perfusion decellularization method in less than 2 h using enzymatic solutions, 1% SDS, 3% TX100, followed by 4% sodium deoxycholate (SDC). The hearts were recellularized with
multipotential cardiovascular progenitors derived from Y1-iPSCs and after 20 days of culture
and differentiation, beating whole mouse hearts were achieved. An optimized, automated method
was reported by Akhyari et al. [17] and Aubin et al. [178] for decellularization of rat hearts using
1% SDS (w/v), 1% SDC (w/v), 0.05% NaN3 in DI water; 1% saponin, 0.05% NaN3 solutions and
implementing a computer pressure control system through negative-feedback and engineo GmbH
software (www.engineo.com) maintaining 77.5 mmHg (1.5 PSI) pressure throughout the
process.
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The first report of porcine heart decellularization was in 2010 by Wainwright et al. [21]
in which porcine hearts were decellularized using 2X PBS, 0.02% Trypsin in EDTA and NaN3,
3% TX-100, and 4% SDC in 8 hours resulted in 92.2% DNA removal. It was reported that the
amounts of elastin and GAGs per 1 mg of lyophilized sample were not different than those
measured in the native hearts. However, because of the change in density of the samples through
decellularization, elastin and GAGs were lost at a ratio similar to the overall loss in dry weight.
Remlinger et at. [23] in 2012 used the same decellularization method while gradually increasing
the flow rate and implementing a maximum of 2200 mL/min flow rate. In our experiments, the
pressure increase was also automated and controlled by the computer to a maximum flow rate of
2250 mL/min to maintain the set point pressure.
Ultimately, the use of stem cells or iPSCs would be desirable for recellularization.
Therefore, retaining fundamental molecules to signal cell proliferation and differentiation will be
required to mimic the function of healthy hearts. A gentle decellularization method is a
promising process to obtain intact ECM ready for repopulation with stem cells. Further studies
need to be performed to demonstrate the differentiating capacity of these cECM prototypes for
human stem cells.
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4

4.1

USING HEMOLYSIS AS A NOVEL METHOD FOR ASSESSMENT OF
CYTOTOXICITY AND BLOOD COMPATIBILITY OF
DECELLULARIZED HEART TISSUES
INTRODUCTION

In order to use cECM made with a decellularization process in tissue engineering
purposes, it is necessary to obtain very pure cECM samples that are able to support cell growth
without any cytotoxic effects. Due to the use of surfactants in the automated decellularization
process which was described in the previous chapter, it is necessary to remove harmful chemical
residues that could cause cells to become apoptotic, decrease in function, or cause thrombosis in
cardiac tissue samples [179]. Sodium dodecyl sulfate (SDS), a strong detergent that was used to
remove cellular material, was the primary concern for causing cytotoxicity in the experiments
described in this chapter.
This study examined the utility of a hemolysis assay, the lysing of red blood cells [180],
as a novel method to measure cytotoxicity in cECM samples. In order to test this method,
porcine hearts were harvested and then decellularized using the automated bioreactor described
in chapter 3. After decellularization, samples were taken from the left ventricle and rinsed in
phosphate buffered saline (PBS). At various time points, samples were removed from the washes
and tested for cytotoxicity. Human blood was purchased from a local blood bank and tested for
quality and suitability. Erythrocytes from this blood were then added to the samples of washed
cECM and percent hemolysis was calculated. This was done by calculating the percentage of
ruptured erythrocytes in each sample by detecting and measuring the amount of hemoglobin
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present via spectrophotometry [181]. In order to further assess cytotoxicity, mouse endothelial
cells (MS1) were seeded onto the cECM samples. With the assistance of cell staining, it was
possible to visualize the healthy and apoptotic cells on each sample. In addition to increased
cytotoxicity, another negative side effect of prolonged SDS exposure is the degradation of
collagen and other proteins in the cECM. Collagen is an abundant protein in cardiac tissue and is
essential for providing structure to the heart [169]. The amino acid hydroxyproline was used as a
marker to measure the amount of collagen contained within each sample [182]. Once the amount
of collagen was quantified, it was compared against a standard curve of known collagen
concentrations to determine the amount of collagen preserved after decellularization.
4.2
4.2.1

MATERIALS AND METHODS
HARVESTING AND DECELLULARIZATION

The harvesting and initial decellularization protocol was similar to sections 3.2.1, 3.2.2
and 3.2.3. Two different protocols for decellularization were used as described in Table 4-1.
Table 4-1. Decellularization protocols for SDS and TX-100 groups

SDS
Group

TX-100
Group

1X PBS

DW

0.5% SDS

DW

0.5% SDS

DW

0.5% SDS

1h

1h

2h

1h

2h

1h

2h

1X PBS

DW

0.5% SDS

DW

0.5% SDS

DW

0.5% SDS

DW

1% TX-100

1h

1h

2h

1h

2h

1h

2h

overnight

2h

SDS: sodium dodecyl sulfate; DW: distilled water; TX-100: Triton X-100
In the SDS group, decellularization was done similar to section 3.2.3 but without the
rinses after the last 2 hours of SDS solution perfusion. In the Triton X-100 (TX-100) group,
hearts were perfused with similar solutions to the SDS group for similar amounts of time and in
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the same order. After the last 2 h wash with SDS solution, the hearts were perfused with 10 L of
distilled water, recycled for 8 h overnight, followed by 2 h of 1% (v/v) TX-100 perfusion
Subsequent to the final detergent perfusion with either SDS or TX-100 in both groups,
the hearts were removed from the decellularization apparatus and the left ventricles were
dissected. Samples of decellularized myocardial cECM from the left ventricular wall were
obtained, minced and mesh-standardized specimens of 2 × 2 × 2 mm were made from each heart
and placed in a beaker filled with 4 L of 1X PBS that was continuously stirred at 60 rpm with a 5
cm stir bar. The left ventricle wall is the thickest portion of the heart and is highly vascularized,
therefore it is most probable that the majority of cytotoxicity would be found in the left ventricle.
Three liters of the 1X PBS solution were renewed every 24 h. Ten samples were removed from
the solution at various time points (approximately every 5 h) with a maximum interval of 10 h
between each time point, then stored at 4 °C to be used for hemolysis assay, cell proliferation
and cytotoxicity assays, collagen and residual SDS content measurements or structural analysis
by scanning electron microscopy.
4.2.2

HUMAN BLOOD TEST: FRAGILITY OF THE ERYTHROCYTES

One to three months post expiration date, anonymous human blood bags were purchased
from the MountainStar Health® (Ogden, UT) blood bank. In order to assure the quality of the
blood and suitability for hemolysis experiments, the fragility of the erythrocytes were measured
using a method based on a study by Parpart et al. [183]. For the fragility assay, 4 sets of 0%,
20%, 40%, 60%, 80% and 100% dilutions of 1X PBS with osmolality of 300 mOsm/L in type
one distilled water (DW) were made. Fifty µL of blood were added to 1 mL of 1X PBS dilutions
in microcentrifuge tubes and mixed gently by manual inversion. After 10 min the tubes were
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centrifuged for 3 min at 3,000 ×g, the supernatant removed, and absorbance measured at 540 nm
to calculate the percentage of hemolysis using the formula in equation below:

%𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 =
Where:

𝐴𝐴 − 𝐴𝐴0
× 100
𝐴𝐴100 − 𝐴𝐴0

A = Absorbance of supernatant of erythrocyte suspension with sample solution
A0 = Absorbance of supernatant of erythrocyte suspension with 100% 1X PBS
A100 = Absorbance of supernatant of erythrocyte suspension with 0% 1X PBS
4.2.3

HUMAN BLOOD TEST: HEMOLYSIS ASSAY

Erythrocytes were separated from human blood by centrifugation at 2,000 ×g for 10
minutes and the supernatant was extracted. Erythrocytes were then diluted in 1X PBS to create
an erythrocyte suspension (ES) with 2 × 109 cells per mL. A Moxi® Z mini automated cell
counter kit (Ketchum, ID) was used to assure the accuracy of the erythrocyte concentration in the
ES. Specimens from each of the time points for the SDS and TX-100 groups were placed in 20
mL glass vials with 5 mL of ES. The vials were then placed on an orbital shaker with 125 rpm
and maintained at room temperature. Vials without any specimens were used as negative controls
and vials with 25 mg of SDS added to the ES were used as positive controls. After 60 min, 1 ml
of ES was removed from each vial, centrifuged for 3 min at 3,000 ×g and absorbance of the
supernatant was measured at 540 nm. Percentages of hemolysis were calculated using the same
equation for percentage of hemolysis with the positive control absorption as A100 and negative
control as A0.
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4.2.4

CYTOTOXICITY ASSESSMENT AND CELL PROLIFERATION

One of the main advantages of the cECM is its ability to support mammalian cells
mechanically and chemically to function and proliferate. Chemicals used during the process of
obtaining acellular scaffolds through decellularization can affect the scaffold’s supportive
properties drastically and cause the cells to become apoptotic or not function well [6]. In order to
assess the cytotoxicity of the cECM and investigate the proliferative properties of mammalian
cells in contact with the cECM, mouse endothelial cells (MS1) were cultured in T-75 cell culture
flasks using a 5% CO2 incubator at 37 °C with 10 mL of growth medium [10% fetal bovine
serum (FBS), 100 U/mL penicillin,100 µg/mL streptomycin] renewed every 2 days. The cells
were detached from the flasks at 80% confluence using 0.05% Trypsin-EDTA and 105 cells were
seeded in each well of 6-well plates. Specimens from various time points of both SDS and TX100 groups were decontaminated by soaking in a sterilization solution of 100 U/mL penicillin,
100 µg/mL streptomycin and 25 µg/mL amphotericin B (Gibco®, Gaithersburg, MD) in 75%
ethanol for 10 min followed by rinsing twice with sterile 1X PBS. The specimens were added to
the 6-well plates 2 days after seeding with MS1 cells and the plates were incubated at 37 °C in a
5% CO2 incubator for 4 h. Wells without any specimen were used as positive controls. The cells
were then labeled using 2 µM calcein AM and 4 µM EthD-III (Biotium® Viability/Cytotoxicity
Assay, Hayward, CA) in order to assess the cytotoxicity of the cECM specimens and a FLoid®
cell imaging station was used to visualize the green and red fluorescence corresponding to
healthy and apoptotic cells, respectively.
4.2.5

COLLAGEN QUANTIFICATION USING HYDROXYPROLINE ASSAY

Collagen is the most abundant protein in the extracellular matrix of mammalian tissues,
and collagens constitute a large family of proteins that each have at least one triple-helical
83

domain. Fibrillar collagens consist of three α chains that have 3 polyproline II helices (lefthanded) twisted in a triple helix (right-handed) staggered by one residue between adjacent α
chains. Interchain hydrogen bonds, electrostatic interactions involving lysine and aspartate, and
the high content of proline and hydroxyproline are the factors that influence the stabilization of
the triple helix [182]. Because hydroxyproline is found mainly in collagen and rarely in other
proteins [184], hydroxyproline content can be used as a marker to measure the amount of
collagen.
To prepare cECM samples for quantification of hydroxyproline, decellularized specimens
from various time points from both the SDS and TX100 groups were collected and then
lyophilized for 2 days. Samples were tested for the presence of hydroxyproline using
BioVision’s Hydroxyproline Assay kit (BioVision™, San Francisco, CA) based on the
manufacturer’s protocol. First, 5 mg of the lyophilized samples were homogenized in 500 ml
distilled water. Then the samples were digested in 500 ml of 12 N HCl at 60°C for one day.
Chloramine T and 4-(Dimethylamino)benzaldehyde (DMAB) reagents from the assay were
added to each sample in a 96 well plate, incubated for 30 min at 60 °C and then the absorbance
of the samples was measured at 560 nm. A standard curve was prepared with a known
hydroxyproline solution to determine the amount of collagen in each sample.
4.2.6

STRUCTURAL ANALYSIS WITH SCANNING ELECTRON MICROSCOPY

The decellularization process makes the cECM porous by removing cellular components
from the tissue; however, over-processing or soaking the cECM in PBS for too long, in order to
remove detergent residues, can alter the porosity. Scanning electron microscopy (SEM) was used
to analyze the porosity and protein conformation of the cECM samples at different time points
from both the SDS and TX-100 groups. Biological sample preparation for SEM can also alter the
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structure of the sample [185, 186]. In order to avoid significant alteration, samples were
minimally processed by soaking the specimens in 50% ethanol (v/v) followed by flash freezing
the specimens by placing them in 1L of 100% ethanol, cooled down to about -150 °C using
liquid nitrogen. Frozen specimens were immediately placed in a lyophilizer and dried for 5 days.
Specimens were then attached to SEM stubs using carbon tape, coated with 3 nm of platinum
and placed in a Helios NanoLab™ 600 Focused Ion Beam/SEM (FEI™, Hillsboro, OR) for
image acquisition.
4.2.7

SDS MEASUREMENT USING A COLORIMETRIC METHOD

As previously reported by Jurado et al. Rosconi et al. [187, 188] amounts of SDS in
hydrophilic solutions can be quantified using colorimetric methods. In this study, specimens
from both SDS and TX-100 groups, collected at different time points, were placed in 1 mL DW
on a shaker for 24 hours at room temperature. Standards solutions of 0 to 10 mg/L SDS in
distilled water were created for calibration. A 50 mM buffer solution of sodium tetraborate
(Na2B4O7, by Sigma-Aldrich®) was prepared and the pH was adjusted to 10.5 by using a dilute
solution of sodium hydroxide. To color the SDS, 0.1 g of methylene blue reagent was dissolved
in 100 mL of borate buffer solution (10 mM) with adjusted pH 5-6. The methylene blue solution
was kept in a topaz-colored flask. In a glass test tube 10 µL of phenolphthalein was added to 5
mL of diluted SDS sample or standard solutions. The solution were alkalinized with addition of
200 µL of sodium tetraborate at pH 10.5 to the color change of phenolphthalein. Next, 100 µL of
stabilized methylene blue solution and 4 mL chloroform (CHCl3, Sigma-Aldrich™) were added
to the SDS solutions. Before each measurement, the glass test tube was stirred vigorously for 30
s and allowed to rest for 10 min. The chloroform phase was used for colorimetric measurements
with UV-vis quartz cuvettes at 650 nm against pure chloroform.
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4.2.8

STATISTICAL ANALYSIS

Statistical analysis of the results from the experiments described in this chapter was
similar to section 3.2.14. Student’s standard t-test was used for analyzing the data in two groups
of SDS and TX-100. In the cytotoxicity assay, ImageJ v1.49, which is available in the public
domain, was used to calculate the percentages of live and dead cells in random acquired images.
4.3
4.3.1

RESULTS
WHOLE HEART DECELLULARIZATION

A total of 10 hearts were processed for this study. Five hearts were processed for the SDS
group and 5 for the TX-100 group based on the protocol shown in Table 4-1. Figure 4-1 shows a
processed heart from the TX-100 group after 2 h of TX-100 perfusion. After processing, all
hearts were dissected open and the left ventricles were minced to obtain at least 200 specimens
of 2 × 2 × 2 as shown in Figure 4-1.
4.3.2

ERYTHROCYTE FRAGILITY

In order to assure the quality of blood used in the hemolysis experiments, erythrocyte
fragility was determined by suspending the blood in different osmotic solutions. Blood samples
(n=6) were incubated in the various solutions for 10 min and the percentage of hemolysis was
recorded using light absorption at 540 nm.As shown in Figure 4-2, solutions of 40%, 60% and
80% 1X PBS (120, 180 and 240 mOsm/L) produced hemolysis percentages of 97.57% ± 4.23,
58.74% ± 8.82 and 6.94 ± 5.96, respectively. A representative image of the supernatant color
obtained after centrifugation with the various 1X PBS solutions with respect to the percentage of
hemolysis produced is also shown in Figure 4-2. To assure the quality of the results from this
assay, the data were compared to an established fragility standard curve for verification9.
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Figure 4-1. Representative native (left) and decellularized (right) porcine hearts after TX100 treatment. The hearts were decellularized in an automated apparatus through
retrograde aortic perfusion. Hearts from the SDS group were taken out of the bioreactor
after 6 hours of SDS exposure while hearts from the TX-100 group were perfused with an
additional 2 hours of TX-100. Subsequently, hearts were dissected and 2 mm minced
samples from left ventricle walls were obtained (shown by the arrow).

Figure 4-2. Fragility test of human blood. Human erythrocytes were suspended at different
concentrations of 1X PBS (300 mOsm/L) in distilled water for 10 minutes. Hemolysis
percentages were calculated using 540 nm light absorption of the supernatant solutions
after centrifuging. Color bar on the right represents the supernatant after centrifuge with
respect to the percentage of hemolysis.
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4.3.3

HEMOLYSIS ASSAY

Various chemicals used in the process of decellularization can have different effects on
the tissue ultrastructure, mechanical behavior and the biochemical composition, which may
affect the subsequent host response to the material. Chemicals are specifically chosen for use in
the process due to their inherent potential to damage cell membranes. Thus, if they remain in the
cECM after the decellularization process, it is likely that the cECM will be cytotoxic [6, 8]. In
order to assess the cytotoxicity of the cECM in this study, specimens (n=6) collected at different
time points from both the SDS and TX-100 groups were placed on an orbital shaker at 125 rpm
in glass vials containing 5 ml of ES at room temperature for 1 h. It was observed that shorter
periods than 60 min led to unreliable results due to incomplete reactions between the residual
surfactants and erythrocytes. This observation was also reported by Krzyzaniak and Yalkowsky
[189].
As shown in Figure 4-3.A-B, both SDS and TX-100 samples with no wash time produced
greater than 90% hemolysis (90.16 ± 25.66 and 91.42 ± 13.84, respectively). No statistically
significant difference between the SDS and TX-100 groups (p > 0.05) was observed until the 5 h
time point, at which point the SDS group produced 72.38% ± 10.37 hemolysis while the TX-100
group produced 25.61% ± 16.12 hemolysis. The statistical difference between the SDS and
TX-100 groups continued to be significant until the 40 h time point at which time the specimens
in the SDS group produced 8.19% ± 4.31 hemolysis. It was observed that the minimum amount
of required wash to reach no statistical significant difference with the negative control was 10 h
for the TX-100 and 40 h for the SDS group. For the modeling of the cytotoxicity dilution,
decaying exponential functions were fitted to the data. As shown in Figure 4-3.C models based
on the functions of %Hemolysis = 90.16×e -0.06t and %Hemolysis = 91.42 × e -0.25t can represent
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the data for the SDS and TX-100 groups respectively. The models show that the TX-100 samples
have a 4.17 times smaller time constant than the SDS samples which means that the Hemolysis
percentage drops 4.17 times faster in the TX-100 samples compared to the SDS samples.
4.3.4

CYTOTOXICITY ASSESSMENT

Cytotoxicity of the cECM was measured by counting the number of dead versus live cells
using the Biotium® Viability/Cytotoxicity assay. The polyanionic dye calcein provided in the
assay is absorbed by live cells and produces a uniform green fluorescence. The EthD-III enters
cells with damaged membranes and after binding to mammalian cell nucleic acids, the
fluorescence intensity increases by 40-fold and produces a red fluorescence in dead cells. SDS
and TX-100 chemicals used for decellularization in this study are inherently able to damage the
cell membranes and cause toxicity, thus the Viability/Cytotoxicity assay can be used to
determine the level of cytotoxicity.
Although the FBS used in growth medium is known to have neutralizing inhibitors and
digestive capacities [15], it was observed that specimens (n=4) from both SDS and TX-100
groups at 0 hour produced 97.35% ± 1.52 and 94.75% ± 3.42 dead cells, respectively, as shown
in Figure 4-4.A-B.
A statistically significant difference between SDS and TX-100 groups was observed at
the 10 h time point with the SDS group producing 51.94% ± 10.46 dead cells while the TX-100
group produced 7.86% ± 2.53 dead cells. The percentage of dead cells was observed to be higher
for the SDS group until the 40 h time point when no statistically significant difference was
observed between the SDS and TX-100 groups (p value > 0.05). For the TX-100 group after 10
h, no statistically significant difference was observed compared to the negative control (p value <
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0.05), whereas the time point at which there was no statistically significant difference was 40 h
for the SDS group. Representative images of the cells in contact with the specimens from both
groups, labeled with Viability/Cytotoxicity assay are shown in Figure 4-4.C-J.

Figure 4-3. Hemolysis percentages of ES in contact with decellularized specimens from SDS
(A) and TX-100 (B) groups at various time points. Decaying exponential functions fitted to
the data for SDS and TX-100 groups (C). Time axis represents the amount of time in which
the specimens were washed with 1X PBS in order to remove residual cytotoxic detergents
from the decellularization process and the hemolysis axis represents the percentage of red
blood cells that were ruptured due to contact with the specimens.
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Figure 4-4. Cytotoxicity/viability assay on MS1 cells incubated for 4 hours with specimens
from both SDS and TX-100 groups collected at various time points. Quantified percentages
of live cells are shown in green bars (A, B). Representative fluorescence images of MS1 cells
labeled with cytotoxicity/viability assay after 4 hours of incubation with specimen from the
SDS (C-F) and TX-100 (G-J) groups
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4.3.5

COLLAGEN QUANTIFICATION USING HYDROXYPROLINE ASSAY

Stabilization of the triple helix in collagen is primarily due to interchain hydrogen bonds,
electrostatic interactions involving lysine and aspartate, and the high content of proline and
hydroxyproline [182]. Soaking the cECM in PBS for too long, in order to remove detergent
residues, can potentially deteriorate the factors involved in the stabilization of the collagen and
solubilize this protein. In order to investigate the changes in the amounts of collagen,
hydroxyproline content in specimens (n=3) at different time points were measured per milligram
of dried tissue in both SDS and TX-100 groups. Although the averages of hydroxyproline
content in both of the SDS and TX-100 groups declined over 110 and 75 hours, respectively, the
statistical difference was not significant (p-value > 0.05). As shown in Figure 4-5, the contents of
hyroxyproline in the SDS group started at (0 hour) 24.16 ± 6.93 µg/mg of lyophilized tissue and
reduced to 18.88 ± 8.33 µg/mg of lyophilized tissue after 110 h. In the TX-100 group the
contents were observed to start at 23.84 ± 7.39 µg/mg of lyophilized tissue and after 75 h
decreased to 20.43 ± 2.19 µg/mg of lyophilized tissue.

Figure 4-5. Quantified amounts of hydroxyproline as a marker for collagen in the SDS
(left) and TX-100 (right) groups as a function of wash time in 1X PBS
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4.3.6

SCANNING ELECTRON MICROSCOPY STRUCTURAL ANALYSIS

As previously reported [20, 190, 191], surface structural analysis can be performed using
SEM techniques to assess the alignment of collagen fibers. In this study, samples at various time
points were flash frozen, lyophilized for 5 days and coated with 3 nm of platinum.
Representative SEM images acquired from samples at different time points are shown in
Figure 4-6. In both of the SDS and TX-100 groups, samples with longer wash times
demonstrated more dissociation and disruption of fiber alignment.
4.3.7

SDS COLORIMETRIC ASSAY

The colorimetric assay with UV-vis detector was used to measure the amount of SDS in
different samples. To obtain the linear range of SDS solutions, the correlation between
absorbance and concentration was identified. A calibration curve was prepared for different SDS
amounts in the range of 0-20 mg/L. The adjusted regression of 0.996 showed a linear correlation
between the absorbance and different SDS concentrations and consequently the precision of the
applied procedure. Soluble SDS content in the specimens were then calculated using the
calibration curve as shown in Figure 4-7.
As shown, the concentration of SDS in the specimens started at 894.32 ± 55.45 and
753.81 ± 48.57 µg/mL in the SDS and TX-100 groups respectively. In the TX-100 group the
concentration decreased to 6.99± 0.57 µg/mL after 21 hours, while at a similar time point in the
SDS group, the concentration was observed to be 98.06 ± 6.08 µg/mL. After 50 hours, SDS
contents in the SDS and TX-100 groups did not demonstrate a statistically significant difference
and the concentration was 5.09 ± 0.57 µg/mL in the TX-100 group.
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Figure 4-6. SEM images acquired from cECM samples at different time points from the SDS
and TX-100 groups. Arrows show dissociated collagen fibers with disrupted alignment
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Figure 4-7. Concentration of SDS in 1 mL distilled water incubated for 24 hours with
specimens from both SDS and TX-100 groups collected at various time points.
Concentrations were measured using a colorimetric assay containing methylene blue and
chloroform. The image on the graph shows the test tubes containing standard solutions of
SDS in two hydrophilic (top) and hydrophobic (bottom) phases. Note the more saturated
blue colors in test tubes containing higher concentration of SDS standard solutions
4.4

DISCUSSION

Natural extracellular matrices have been shown to be promising scaffolds with tissuespecific potential to support cell growth and differentiation [192-194]. They can be obtained by
decellularization of native tissue either by perfusing detergent solutions through the vasculature
or diffusion of this solution through pieces of tissue [158]. This procedure removes any cellular
materials from the matrix that might cause immune reaction after transplantation. Sodium
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dodecyl sulfate is by far the most preferred agent for removing cell debris [3, 195]. However, as
a strong ionic detergent, SDS can denature proteins [196, 197] and damage phospholipid
membranes [198] leading to cell necrosis [199]. Accordingly, one should take sufficient care to
remove residual SDS after the decellularization process. This critical issue increases the need for
a standard method to evaluate cECM cytotoxicity after decellularization.
In this chapter, a novel, covenient, and rapid method to examine cytotoxicity of acellular
cECM was developed. There were several previous chemical methods for quantification of
residual SDS [187, 188, 200], but there was still a need to determine a threshold for SDS
concentration leading to cell toxicity. Disruption of red blood cells due to SDS contact is a
relevant indicator that I used to measure cytotoxicity of cECM. This hemolysis assay is a
practical method that directly measures cell death caused by SDS presence that can also be
applied to any other tissue or scaffold. Data shown in Figures 4-3 and Figure 4-4 suggest that the
hemolysis assay results are generally consistent with the cell viability assay results on acellular
tissue (e.g. samples with <20% hemolysis also show <20% dead cells), which is a critical factor
in preparation of cECM.
Our data also support the use of Triton X-100 to extract retained SDS trapped in the
structure of cECM as suggested by previous researchers [3, 201]. SDS is a relatively small ionic
molecule that can diffuse through the collagenous fibers and get trapped there because of its
ionic nature [202]. As shown in Figure 4-6, relying just on PBS washes to remove SDS would
result in dissociated collagen fibers that not only affects the mechanical strength of cardiac tissue
but also might change the seeded cell proliferation and gene expression patterns. TX-100 is a
non-ionic detergent that can bind to SDS and facilitate its removal from the cECM, as previously
reported [30].
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To summarize, in this chapter the hemolysis assay was introduced as a rapid colorimetric
method that can be used to examine certain aspects of cytotoxicity of a tissue or scaffold due to
residual detergents. More studies need to be performed to see if this assay can be used for other
cytotoxic agents such as peracetic acid or ethanol, which are common sterilizing chemicals in
biomedical applications. Additional optimization of the hemolysis assay (e.g. ratio of tissue to
red cells, contact time) would improve the utility and versatility of the assay.
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5

5.1

CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLDERIVED CARDIOMYOCYTES ON ACELLULAR ECM SLICES FROM
WHOLE DECELLULARIZED PORCINE HEARTS
INTRODUCTION

Since the emergence of tissue engineering [203] the field has encountered paradigm shifts
such as the introduction of human induced pluripotent stem cells [204] and using whole organ
decellularization technology. The heart has very limited regeneration capability and an infarction
causes loss of about one billion cardiomyocytes, diminishing the pumping function of the heart
[155]. The purpose of cardiac tissue engineering is to repair or replace the damaged portion of
the heart by generating biocompatible tissues that are fully functional and durable, capable to
grow with the recipient [174]. As previously discussed in the first chapter, Table 1-2, various cell
types have been introduced for the regenerative medicine purposes. Fetal cardiomyocytes,
fibroblasts, smooth muscle cells and various types of stem cells such as embryonic, bone
marrow, hematopoietic and induced pluripotent have been studied in cardiac tissue engineering
and they have demonstrated varying levels of success in myocardial regeneration [205].
Induced pluripotent stem cells have unlimited self-renewal capability while retaining
differentiation potential [206]. Through optimized staged differentiation protocols, these cells
can be implemented for cardiac differentiation with high efficiency [207, 208]. Variability of
differentiation efficiency, heterogeneity in the differentiated cardiac cell population, scale-up
difficulties and immaturity of the differentiated cardiac cells are the challenges that currently
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exist. One of the effective tissue engineering approaches for overcoming these issues is
designing systems based on biomaterial scaffolds [206].
In this chapter, the effectiveness of porcine cardiac extracellular matrix (cECM) as a
supporting scaffold for cardiomyocytes (CMs) differentiated from human induced pluripotent
stem cells (iPSCs) was demonstrated. Acellular cECM was produced in an automated, pressurecontrolled whole heart decellularization apparatus (as described in Chapter 3) and human iPSCs
generated from peripheral blood monocytes (according to the study by Riedel et al. [209]) were
used for CM differentiation. Differentiated CMs on cECM exhibited improved phenotype
maintenance, elongation, arrangement and beating function compared to regular cell culture
plates.
5.2
5.2.1

MATERIALS AND METHODS
DECELLULARIZATION AND SAMPLE PREPARATION

The procedures for harvesting and decellularization are described in sections 3.2.1, 3.2.2
and 3.2.3. After the final TX-100 perfusion, the hearts were perfused with non-recycled water for
a minimum of 4 h followed by perfusion of 5% ethanol for 30 min. Perfusing the heart with 5%
ethanol makes the frozen cECM less brittle at -21 °C which is helpful for slicing with a cryostat
machine. Decellularized hearts were then removed from the apparatus, dissected open and the
left ventricles were separated. A cryostat machine (HM525 NX, Thermo Scientific®, Pittsburgh,
PA) was used to make 300 µm slices and a 12 mm biopsy punch (Acuderm® Inc., Fort
Lauderdale, FL) was used to make round cuts. The slices were mounted on 10 mm round
coverslip (Ted Pella®, Redding, CA) with the corners hooked to the other side of the glass by
pressing them with another coverslip. Coverslip-mounted samples were placed in 48-well plates
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and 1 mL of an antibiotic solution containing 100 U/mL penicillin, 100 µg/mL streptomycin, 25
µg/mL amphotericin B in 75% ethanol was added to each well. The samples were incubated for
2 h at room temperature on a rotary shaker. Each well was then washed 3 times with sterile PBS
and the plates were centrifuged at 1500 ×g to remove trapped air bubbles from the wells. Each
well was then filled with 500 µL of Dulbecco's Modified Eagle Medium (DMEM, Gibco™),
pre-warmed to 37 °C and the 48-well plates were stored at 4 °C for up to 2 weeks. Warming the
DMEM is advantageous in deaeration of the medium and preventing bubbles forming on the
cECM.
5.2.2

CHARACTERIZATION OF THE CECM

In order to demonstrate the acellularity of the cECM slices, amounts of residual DNA in
the cECM were measured and compared to the native heart samples without decellularization.
DNA content measurement was performed using the protocol described in section 3.2.4.
For surface characterization and porosity analysis of the decellularized cECM, 5 mm × 5
mm × 5 mm samples were prepared for SEM with sample preparation and image acquisition
protocols similar to section 4.2.6.
5.2.3

CELL CULTURE AND DIFFERENTIATION

Human iPSCs generated from peripheral blood monocytes (PBMCs) as previously
described by Riedel et al [209], cryopreserved at -190°C were used in this study. The cells were
thawed and seeded in 6-well plates, coated with vitronectin (VTN-N, Gibco™) based on the
manufacturer’s protocol. Growing and expansion of human iPSCs was performed in Essential
8™ medium (Gibco™) and StemPro® Accutase® (Gibco™) was used as a cell dissociation
reagent to detach the iPSCs from plates when passaging at 85% confluence. Cell suspensions
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were centrifuged at 160 ×g for 3 mins and the dilution of passaging was optimized to achieve
85% confluency in 3 to 4 days. Rho-associated protein kinase (ROCK) inhibitor (RevitaCell™,
Gibco™) was added to the cell suspensions for the first 24 h after each passage to improve the
survival rate.
Cardiomyocyte (CM) differentiation of iPSCs was performed on monolayer cultures and
the process was controlled visually. The differentiation process included stage-specific
application of growth factors and small molecules and was based on the embryo’s cardiac
developmental program. Three stages of differentiation consisted of a mesodermal differentiation
(Stage-1) followed by cardiac progenitor cell differentiation (Stage-2) and finally, differentiation
into cardiomyocytes (Stage-3). Starting on day 0, differentiation was started on 90% confluent
iPSCs by replacing the Essential 8™ medium with a DMEM/F12 medium supplemented with B27® without insulin (Gibco™) and Activin A (50 ng/mL). On day 1, the medium was replaced
with fresh DMEM/F12 medium supplemented with B-27® without insulin, plus basic fibroblast
growth factor (bFGF) and bone morphogenetic protein 4 (BMP4), 10 ng/mL each. On day 3,
DMEM/F12 medium supplemented with B-27® without insulin, but supplemented with a WNT
signaling pathway inhibitor (C59) was given to the cells. On day 5, the medium was replaced
with complete cardiomyocyte medium (B-27®-supplemented RPMI based) and renewed every 3
days.
5.2.4

RECELLULARIZATION OF THE CECM SAMPLES

On day 4 of the differentiation process, the cells were dissociated using 1 mL of
TrypLE™ (Gibco™) enzyme. After centrifugation at 160 ×g for 3 mins, the cells were
resuspended in complete cardiomyocyte medium. A Moxi Z™ (Orflo™, Ketchum, ID)
automatic cell counter was used to count the cells and the cell suspensions were diluted to a
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concentration of 2×106 cells/mL. ROCK inhibitor was added to the cell suspensions and 500 µL
was then pipetted to each well of the 48-well plates including the coverslip-mounted cECM.
Plates were then placed in a 37 °C incubator with 5% CO2 and the media was renewed every
other day. CellTracker™ Green CMFDA Dye (Molecular Probes™) was used according to the
manufacturer’s instructions in order to label the cells reseeded on the cECM. From the stock
1000X dye, 0.5 µL were added to 500 µL of media and the cells were incubated for 30 mins in
37 °C incubator with 5% CO2. Media was then replaced with complete cardiomyocyte media and
an EVOS™ FLoid™ Cell Imaging Station (Thermo Fisher Scientific®) was used to visualize the
cells adhered to the cECM.
5.2.5

VIABILITY ASSAY

Assessment of cell viability and cytotoxicity of the experiments was performed using a
resazurin-based reagent (Molecular Probes™, Carlsbad, CA) with a protocol modified for human
iPSCs. Immediately after renewing the complete cardiomyocyte medium in 48-well plates, 2.5
µL of the stock 100X reagent was added to each well and the plates were incubated in a 37 °C
incubator with 5% CO2. After 15 mins, 200 µL of the assay media were transferred into black
96-well plates and the fluorescence intensities were measured with an excitation wavelength at
560 nm and emission at 590 nm in a microplate reader (Synergy 2®). Fluorescence intensities of
samples from the 48-well plates containing the cECM were compared to vitronectin-coated 48well plates, without cECM, containing known amounts of cells.
5.2.6

HISTOLOGY AND IMMUNOFLUORESCENCE IMAGING

Histology characterizations of the cECM samples were performed with a similar method
to which is described in section 3.2.8.
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Recellularized cECM samples and undifferentiated iPSCs on vitronectin-coated
coverslips were fixed in 4% paraformaldehyde (Sigma- Aldrich®) in PBS for 1 h. The samples
were then washed with PBS and incubated in membrane blocking solution (Life Technologies™)
at 4 °C overnight. Primary antibodies for cardiac troponin T (cTNT), wheat germ agglutinin
(WGA), SOX2, OCT4, CDH1 (E-cadherin), CDH2 (N-cadherin), all purchased from Life
Technologies™ were diluted 1:100 in the blocking solution and the samples were incubated for 2
h at room temperature. The samples were then washed with PBS and incubated in anti-mouse
and anti-rabbit secondary antibodies (Life Technologies™) diluted 1:100 in the blocking solution
for 1 h at room temperature. NucBlue® reagent (Molecular Probes™) diluted in PBS was then
used to stain the nucleus of the cells. The samples were then mounted on microscope slides with
coverslips using SlowFade® Gold Antifade mountant (Molecular Probes™) and imaged using an
Olympus™ FluoView FV1000 (Center Valley, PA) laser scanning confocal microscope.

5.3
5.3.1

RESULTS
DECELLULARIZATION

Porcine hearts were harvested (n=10) from slaughter size female swine. Decellularization
was accomplished with total SDS exposure of 6 hours in a pressure-controlled apparatus with an
automated pressure increasing function. It was observed that during the first 2 hours of PBS and
distilled water washes, outlet fluids from the vena cava were red, indicating removal of residual
blood and thromboemboli. After the first hour of PBS perfusion, alternating to hypotonic
distilled water, the flowrate was significantly reduced in order to maintain the controlled
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pressure, suggesting an increase in the coronary vessels internal resistance due to the
enlargement of the cells and reduction of coronary vessel sizes.
The hearts were decellularized with similar results to section 3.3.1. Figure 5-1 shows the
results for decellularization performed for the recellularization studies which contains similar
data to Figure 3-2 and 3-3.A. Figure 5-1.A represents a native heart and Figure 5-1.B shows a
heart after the 5% ethanol perfusion in the decellularization process. H&E staining of native
(Figure 5-1.C) and decellularized (Figure 5-1.D) cECM show complete removal of cytoplasm
and nucleus.
Comparing native sirius (Figure 5-1,E) and orcein (Figure 5-1.G) stains to cECM sirius
(Figure 5-1.F) and orcein (Figure 5-1.H) demonstrate retention of general collagen and elastin
fibers after the decellularization process.
Images acquired with SEM show porosity of the decellularized cECM and available
strings of collagenous fibers for cells to attach at 2500X (Figure 5-1.I) and 12000X (Figure 51.J) magnifications. The results from the PicoGreen® assay showed more than 98% decrease in
the amount of DNA after decellularization in the cECM samples. As shown in Figure 5-1.K the
average amount of DNA in the samples from left ventricle of native hearts (n=5) was 691 ng/mg
of lyophilized tissue and decreased to 11 ng/ mg of lyophilized tissue in the decellularized
samples (n=5).
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Figure 5-1. Representative native (A) and decellularized (B) porcine hearts. H&E staining
of native (C) and decellularized (D) samples show removal of cells and debris. Sirius and
orcein staining of native (E,G) cECM compared to decellularized cECM (F,H) demonstrate
retention of general collagen (E,F) and elastin fibers (G,H) after the decellularization
process. SEM images (I,J) show porosity of the decellularized cECM and strings of
collagenous fibers. DNA contents (ng/mg lyophilized tissue) of native and decellularized
samples demonstrate more than 98% DNA removal in the decellularization process.
Histology images were acquired using 10X optical lens and the scale bars represent 100 µm.
SEM images have scale bars for 30 µm (I) and 5 µm (J).
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5.3.2

CELL CULTURE AND DIFFERENTIATION

The healthiest iPSCs with least self-differentiated colonies were observed on the third
and fourth passages after thawing. Figure 5-2.A shows the pathway for CM differentiation of
iPSCs with 3 differentiated stages of mesodermal multipotent stem cells, cardiac progenitors and
CMs. At the cardiac progenitor stage, which was achieved by day 4, the cells were reseeded on
the cECM. Figure 5-2.B shows a slice of cECM mounted on a 10 mm round glass coverslip.
Before initiating the CM differentiation, self-renewal function and pluripotency of the
cells were verified by immuno-staining for OCT4 and SOX2 as represented in Figure 5-2.C-D
with green and red colors respectively. It was observed that by day 2, OCT4 and SOX2 could not
be detected in the stage-1 and stage-2 differentiated cells, as shown in Figure 5-2.E-H. Staining
for N-cadherin and E-cadherin in the differentiating iPSCs at day 0, day 2 and day 4
demonstrated the presence of CDH1 and absence of CDH2 on day 0, which was reversed by
absence of CDH1 and presence of CDH2 on day 2. By day 4, neither E-cadherin nor N-cadherin
could be detected as shown in Figure 5-2.I-N. DAPI blue staining was used in represented
images (Figure 5-2.C-N) for the cell nuclei. Visual appearance of the differentiating cells in 6well plates were examined by light microscopy and the transition of the iPSCs into CMs is
shown in Figure 5-3. Note that the cells elongate and become more opaque during the transition.
5.3.3

RECELLULARIZATION OF THE DECELLULARIZED SAMPLES

One million cells on day 4 were reseeded on coverslip-mounted cECM in 48-well plates
and negative control samples were not reseeded with any cells. It was observed that cECM slices
which were not strongly hooked to the coverslips curled up and became ball-shaped, not suitable
for micro-imaging or video recording. This phenomenon was not observed in any of the negative
control samples. Cells that were adhered to the cECM samples were fluorescence labeled with
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CMFDA followed by fixation and DAPI nuclei staining 24 h after reseeding. Figure 5-4.A shows
a representative stitched image from a recellularized sample with a scale bar of 1 mm.

Figure 5-2. Differentiation of human iPSCs into CMs and recellularization of the cECM
slices. Diagram of the differentiation pathway (A) and a representative image of a slice of
cECM mounted on a 10 mm diameter coverslip (B). Fluorescence immunostaining images
for OCT4, SOX2, e-cadherin (CDH1) and n-cadherin (CDH2) of cells at different stages of
differentiation (C-N) indicates pluripotent, mesodermal and cardiac progenitor cells. DAPI
blue was used in all fluorescence images for staining of the nuclei. All scale bars represent
100 µm.
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Figure 5-4.B presents a 10 times higher magnification on the same sample, illustrating a
confluent presence of reseeded cells on the cECM. After 10 days of culture, various areas of the
cECM started to beat simultaneously and 7 days afterwards, the beating function was improved
by becoming stronger and more synchronized throughout the samples. Figure 5-4.C shows a
stitched image acquired with cTNT immunostaining of a representative beating cECM.
Figure 5-4.D shows a portion of the beating cECM from the same samples on a light transmitted
microscope with relaxed and contracted phases of a representative zone, marked with a blue and
a red line respectively.

Figure 5-3. Visual appearance of the differentiating cells in 6-well plates. Note that the cells
elongate and become more opaque during the transition.
Representative cTNT, WGA and DAPI immunostaining images of CMs derived from
iPSCs, on cECM (Figure 5-5.A) and on vitronectin-coated well plates (Figure 5-5.B) shows
improved arrangement and organization in position of the cells.
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Figure 5-4. A representative stitched image from a recellularized sample with a scale bar of
1 mm (A) and a 10 times higher magnification on the same sample (B) illustrating a
confluent presence of reseeded cells on the cECM 2 days after reseeding. A representative
stitched image acquired with cTNT immunostaining of a beating cECM (C) shows presence
of differentiated CMs throughout the cECM. Contraction of the same sample is shown with
relaxed and contracted phases, marked with a blue and a red line respectively from a
representative zone (D).
Representative videos of beating CMs, 20 days after reseeding, on the cECM sheets
(Supplementary Video-3, accessible online: https://goo.gl/FkznlV) and vitronectin-coated plated
(Supplementary Video-4, accessible online: https://goo.gl/HzqMNd) shows the effect of cECM
in preserving the CM phenotype and improving the beating function. A rotating 3D confocal
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image (Supplementary Video-5 accessible online: https://goo.gl/2VffY4) from a representative
recellularized sample is also available showing the 3D structure of CMs on cECM.

Figure 5-5. Representative cTNT, WGA and DAPI immunostaining images of CMs derived
from iPSCs, on cECM (A) and on vitronectin-coated well plates (B) shows improved
arrangement and organization of the cells.
5.3.4

VIABILITY ASSAY

Based on the assay manufacturer’s instructions, a calibration curve for the fluorescence
intensity of samples versus the number of live cells was made using known amounts of cells in
vitronectin-coated 48 well plates and the regression R square was observed to be 0.99
(Figure 5-6.A). The number of live cells were measured in the recellularized samples (N=3) 1, 2,
4, 10 and 14 days after reseeding. As shown in Figure 5-6.B, the average number of live cells on
the cECM started from (7.48 ± 0.82) × 105 live cells on day 1, increased slightly to (7.56 ± 0.99)
× 105 live cells by day 4 and then declined to (6.80 ± 0.73) × 105 live cells 14 days after
reseeding.
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Figure 5-6. Viability assay for calculating the number of live cells on the cECM. A
calibration curve was made according to the manufacturer’s protocol (A) and the number
of live cells on the cECM was calculated on day 1 to day 14 after reseeding (B).
5.4

DISCUSSION

The pioneering work by Ott et al. brought attention to the potential of using natural ECM
obtained by decellularization, as a scaffold for recellularization and tissue engineering [2]. Since
then the decellularization process has been extensively explored [158] especially in search of
protocols for human-sized organ decellularization. Many different decellularization approaches
have been introduced for hearts [21-23, 25, 123, 194, 210], kidneys [123, 145, 148], lungs [123,
135, 162] and livers [123, 142]. As described in this chapter 3 of this dissertation, for whole
porcine heart decellularization, coronary retrograde perfusion combined with automated
pressure-controlled systems improves the decellularization efficiency.
In this study, decellularization was accomplished with 6 hours of SDS exposure resulting
in residual DNA content lower than the accepted standard for successful decellularization [23].
Due to the denaturing aspect of using SDS in the decellularization process [8], the concentration
of SDS used in this study was lower than other suggested protocols [123] resulting in enhanced
retention of collagen and glycosaminoglycans as shown in chapter 3, Figure 3-4. In addition to
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the biocompatibility, porosity of the scaffolds produced for tissue engineering is an important
design factor [211]. Acquired SEM images from the decellularized samples in this study
demonstrate high porosity as a result of complete cell removal and therefore cECM can be used
as an appropriate scaffold, naturally designed for cell support.
Derivation of embryonic stem cell lines from human sources [212] is very significant in
cardiac tissue engineering because of their ability to proliferate indefinitely in vitro and giving
rise to any tissue. However use of these cells has major drawbacks including requirement of
human embryos for development, raising ethical issues, and immunogenicity difficulties due to
the heterologous source of these cells. Introduction of human iPSCs could largely overcome the
limitations of embryonic stem cells [213]. So far, development of human iPSCs has mostly been
through fibroblast cells and although a skin biopsy might be considered negligibly invasive, a
blood draw is simpler and more acceptable particularly in the infant population [209]. It has been
shown that PBMC-derived human iPSCs can be differentiated into cardiomyocytes with high
efficiency [214] and therefore is useful for myocardial tissue engineering [155]. Nevertheless,
there are limitations for the use of these cells in clinical therapeutics. Limitations such as the lack
of an established method for separating the atrial and ventricular CMs and variability of
differentiation between the iPSC cell lines, should be addressed by further studies and
experimentation. Atrial and ventricular CMs are district in functions and have different
expression of genes. Atrial CMs have shorter duration of action potentials and faster tension
generation/ relaxation rates but create less active tension than the ventricular CMs.
It has been shown that whole heart decellularization can also be used to generate human
cECM [123, 215]. However, due to the variabilities in the hearts from different donors [123],
human hearts might not be a reliable source for cardiac tissue engineering. In contrast, it is
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possible to obtain a controlled population as a source for creating porcine cECM. As
demonstrated in this chapter, slices of porcine cECM were reseeded with CMs derived from
human iPSCs and it was shown that cECM aids in preserving the CM phenotype over time
(Supplementary video 3 and 4, accessible online: https://goo.gl/FkznlV and
https://goo.gl/HzqMNd). CMs attached to the cECM showed arrangement in direction of the
cECM fibers (Figure 5-4 and Figure 5-5.A) which was not observed in the CM samples without
cECM (Figure 5-5.B).
The protocol developed in this study can be used for perfusion recellularization of large
portions of decellularized hearts (e.g. left ventricle) in order to obtain a 3D recellularized
working model. The ultimate goal of cardiac tissue engineering is to create a transplantable
tissue with autologous cells to eliminate immunogenicity and provide enough function to
replenish the loss due to cardiac disease. Many challenges however must be confronted in order
to achieve the ultimate goal. The scaffolds must be repopulated with all of the necessary cell
types in the myocardium including CMs, endothelial cells, vascular smooth muscle cells and
stromal cells such as fibroblasts and pericytes. Robertson et al. [3] showed that addition of
endothelial cells with CMs improves the function of recellularized rat hearts by a factor of 4 and
prevents thrombosis in the transplanted engineered hearts. Appropriate placement of various cell
types into their native positions is also very critical in creating engineered functional tissues
suitable for transplantation [7, 155, 174].
Data from the viability assays indicated that from 106 Stage-2 cells that were reseeded on
the cECM, 0.75 × 106 cells were attached to the scaffold by day 1 resulting in a 75% reseeding
success which is significantly higher than the perfusion reseeding success reported by Lu et al.
[20]. The number of live cells did not change drastically in 14 days demonstrating the limited
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proliferation ability of terminally differentiated CMs which is a well-known characteristic of
these cells [59, 174].
The heart contains dense tissues and a 1 cm2 slice, with 100 µm thickness of an adult left
ventricle, contains approximately 106 CMs [7]. The main challenges involved with culturing a
more dense cardiac tissue are increasing the number of cells on the cECM, and overcoming the
oxygenation and nutrient requirements. Culturing human iPSCs on the cECM and taking
advantage of the highly proliferative stage of the stem cells to confluently repopulate the scaffold
might be a viable approach to achieve a dense tissue. However, in our experiments with culturing
undifferentiated iPSCs on cECM, the adherence of stem cells to the scaffold was very
insignificant (data not shown). The reason for this observation might be the lack of iPSCs’
integrin repertoire involved with adherence to collagen-I, which is the main component of ECM
[126, 128, 216].
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6
6.1

DISSERTATION SYNOPSIS
CONCLUSIONS

As discussed in chapter 1, the strategy of whole heart decellularization followed by
recellularization with autologous cells has significant advantages in cardiac tissue engineering
and regenerative medicine therapies. Although rodent models are beneficial in providing initial
results and proof of concept for cardiac tissue engineering, a scale-up is necessary to make the
strategy useful for mankind. In this research I found that generally, decellularization of porcine
hearts is more challenging than murine hearts and can take much longer which is due to the
larger size and structural complexity of porcine hearts.
In this study, porcine hearts were harvested fresh from a local abattoir and a protocol was
developed for effective preparation of the hearts for decellularization. The developed protocol
(section 3.2.1) enables an inexpensive source for obtaining organs for tissue engineering research
and contains important details such as the necessary wash of the heart with 10 Units/mL
heparinized PBS, and antibiotics. I found that the successful decellularization most likely fails if
the hearts are not washed with heparinized PBS thoroughly after harvesting.
The automated pressure controlled apparatus that was described in section 3.2.2 provides
accurate control on the flow pressure on the heart during the decellularization process. The
gradual pressure increase that is added to the computer programming of the controller also plays
an important role in maintaining the vasculature and the aortic valve of the hearts intact. I
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observed that a sudden increase in the pressure on the heart damages the aortic valve and results
in unsuccessful decellularization.
The resulting acellular cECM contained 11 ng of DNA per mg of lyophilized tissue
which is well below 50 ng/mg established criteria for successful decellularization and
demonstrating 98% cell removal. In the macrophage stimulation assay, cECM samples
demonstrated limited potential for causing an immune response. I found that culturing
macrophages is more challenging than most other mammalian cells because they don’t adhere to
the plates and as stated in section 3.2.6, it’s important to use DMEM without phenol red to avoid
interferences in the Griess assay.
As shown in Figure 3-4, the developed decellularization assay demonstrated retention of
the GAGs particularly in the left heart and collagen proteins almost throughout the heart.
Although the Sircol® assay for collagen quantification produced reliable results, I found the
hydroxyproline assay described in section 4.2.5 more user friendly and accurate.
The cECM samples exhibited a high capacity for recellularization. I designed and created
a perfusion bioreactor and recellularized the decellularized right ventricle of the hearts with
human fibroblasts and endothelial cells. Perfusion of the endothelial cells through the vasculature
was effective in the attachment of endothelial cells to the lumen of the blood vessels throughout
the vasculature. Fibroblast cells were injected in particular areas of the tissue and as shown in
Figure 3-8, they have less dispersion through the tissue. Major challenges that I had in this part
of research were preventing bacterial contamination of the cell culture medium during
recellularization as well as proper aeration of the medium. Due to foaming, the use of a bubble
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aerator is not possible; therefore I used sterile gas flow in the bioreactor and added stir bars to
agitate the medium.
In chapter 4 of this dissertation, I demonstrated the novel use of a hemolysis assay for
determining the cytotoxicity of decellularized heart tissues due to residual chemicals used in the
decellularization process. I showed that the removal of SDS was accelerated by a factor of 4 by
introducing an additional 2 h of TX-100 wash in the decellularization process. The cytotoxicity
of the cECM samples was eliminated in the TX-100 group after 10 h of PBS wash compared to
40 h when not including TX-100 in the process. The results from the hemolysis assay were
shown to be consistent with the established cell viability live/dead assay on endothelial cells in
contact with cECM specimens.
In addition, SEM images of the cECM showed the adverse effects of prolonged (up to
100 h) exposure to SDS and TX100 on collagen and the tissue structure. The preparation method
that I developed and described in section 4.2.6 for SEM sample preparation includes flash
freezing the sample in a frozen ethanol slurry and is much faster and less destructive compared to
standard fixation and dehydration methods. However, the tissue samples still needed to be coated
with conductive elements and the coating process, and if not performed carefully can alter the
surface characteristics of cECM.
I was trained on how to maintain and expand cultures of human induced pluripotent stem
cells and human peripheral blood monocyte derived iPSCs were obtained from Dr. TristaniFirouzi at the University of Utah. Although the stem cell research has advanced significantly
during the past couple of years, methods and strategies for maintaining a healthy population of
iPSCs and differentiating them into cardiomyocytes are still imperfect and improving. Human
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iPSCs need very special care. Requirements such as the need for renewing the iPSC’s medium
every day due to denaturation of bFGF and auto differentiating colonies in culture flasks are
challenges in working with human iPS cells.
As described in chapter 5, the cells were successfully differentiated into beating
cardiomyocytes in a directed differentiation pathway. The cells were directed to differentiate into
a mesodermal cell type followed by cardiac progenitor and fetal cardiomyocyte phenotypes.
Figure 5-2 shows the pathway protocol that was developed for differentiation of human iPSCs
into CMs and reseeding them onto cECM. SOX2 and OCT4 genes were used as markers for
pluripotency and CDH1 and CDH2 were used for mesoderm stage verification of the cells.
Finally, differentiated CMs expressed cardiac troponin T which is shown in Figure 5-4 and
Figure 5-5.
I decellularized whole porcine hearts in the automated, pressure-controlled apparatus as
described in chapter 3, and prepared 300 µm slices of cECM for recellularization. A cryostat at 20 °C was used for making slices and because the 300 µm required thickness for the
recellularization slices was relatively higher than standard cryostat sectioning thickness; frozen
cECM samples could not be sliced without breakage. In order to solve that problem a subsequent
step of 5% ethanol perfusion was added to the decellularization process and as a result the frozen
cECM samples became less brittle and intact slices of 300 µm could be created. Another issue
was that reseeded cECM slices curled up after one day, creating a spherical-shaped tissue not
suitable for filming and imaging. In order to solve the problem, cECM slices were mounted on
glass cover slips with the corners folded over and pressed against the glass.
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The protocol that was developed for differentiating iPSCs into CMs and reseeding them
on cECM slices was described in sections 5.2.3 and 5.2.4. Using that protocol acellular cECM
slices were recellularized with human CMs. After 10 days the scaffolds started to beat and it was
shown that cECM improves the overall function of the CMs by preserving the CM phenotype
and arrangement of the cells.
In this study, slices of cECM were recellularized with CMs differentiated from human
iPSCs. In the developed protocol, differentiation started in cell culture plates and differentiating
cells at cardiac progenitor stage were reseeded onto the cECM. It was shown that the number of
viable cells decreased after reseeding and did not increase during 14 days of culture. My
preliminary results from culturing human iPSCs on cECM before initiating the differentiation
were not successful and the cells that attached to the cECM did not survive.
The described methods in this dissertation enable the combination of human iPSCs as an
autologous cell source with porcine acellular cECM as the scaffold for mechanical and
biochemical cell support in order to create a functional cardiac tissue. This method can be used
for tissue engineering and regenerative medicine therapies in the future.
6.2

RECOMMENDATIONS FOR FUTURE STUDIES

In this study a decellularization process was optimized based on using SDS as the main
surfactant to remove the cellular debris. Although the decellularization process was shown to be
effective in creating cECM acceptable for cardiac tissue engineering, downsides such as the
necessary prolonged washes to remove cytotoxicity still exist. I therefore suggest additional
research on decellularization with various materials.

121

As an example, my preliminary results from decellularization with a 0.1 N solution of
sodium hydroxide instead of SDS, showed a decrease in the overall decellularization time. The
concentration of NaOH that I used for decellularization was 25 times lower than that for vascular
corrosion casting and the decellularization was performed at room temperature. Sodium
hydroxide creates a very corrosive base at high concentrations (>1 N). On the other hand, for
centuries people have been making soap by mixing fat and caustic soda in a process called
saponification. Cellular membranes mostly consist of phospholipid layers and it is possible that
caustic soda reacts with the phospholipids, creating surfactants that help in decellularization of
the organ without damaging extracellular proteins.
This hypothesis can be tested and analyzed by decellularizing hearts with various
concentrations of NaOH, measuring the remnant DNA contents as well as collagen and GAGs.
SEM imaging and recellularizing capacity of the decellularized cECM must also be studied to
ensure that the basic solutions do not adversely alter the cECM protein structures.
Although decellularization with NaOH might be advantageous in ways, many challenges
are involved with using basic solutions that need to be dealt with. These challenges are large
disposal volumes of basic solutions and optimizing the decellularization process to enhance cell
attachment to the cECM in the recellularization process.
In order to perform 3D recellularization of the cECM, special bioreactors need to be
designed to overcome challenges such as aeration of the growth medium, maintaining the
sterility and optimizing the amount of required medium in the bioreactor. The designed
bioreactors can consist of several chambers for purposes like aeration or decontamination,
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reservoirs for holding the growth medium and a main chamber that is large enough for whole
heart recellularization.
For future studies, I recommend designing a bioreactor with a larger chamber for whole
heart recellularization and advanced control systems. A similar control system as described in
section 3.2.2 can be created to control the environment during recellularization. Concentration of
CO2 and pH of the medium can be monitored with special sensors and the data can be used to
control the flow rate of the perfusion and determine when the media needs to be renewed. This
bioreactor can be used for recellularization of whole hearts or portions of the heart with various
cell types such as HUVECs, HCFs and eventually iPSCs differentiated into CMs.
Engineering the cECM in order to enhance the non-differentiated iPSCs attachment to the
scaffolds has also great importance and I recommend performing studies in this regard. Having
the iPSCs attached to the cECM eliminates the need for expanding the cells in cell culture flasks
and improves the overall viability of the differentiated cells by avoiding the dissociation step.
Methods such as coating the cECM with vitronectin, laminin or fibronectin can be studied for
engineering the cECM. Human iPSCs can then be reseeded onto the coated cECM and after 24 h,
the cells can be fluorescently labeled with calcein and imaged with confocal laser scanning
microscopy. Resazurin based assays similar to section 5.2.5 can also be used to check the
viability of the cells on the cECM.
Another recommendation for future studies is 3D recellularization of the cECM in a
perfusion bioreactor. However, for recellularizing large portions of the hearts such as the right
ventricle, great numbers of cells are needed (1 billion cells) which makes it expensive and labor
intensive. Therefore I suggest starting with smaller areas of the heart that can be cannulated and
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used for 3D recellularization. CMs or iPSCs can be injected or perfused into the cECM in a
similar way to section 3.2.12 and cultured for 10 days. Histology and immunofluorescence
staining can be used to determine the efficiency of the recellularization and cell types that
repopulate the cECM.
In addition, co-cultures of various cell types such as human endothelial cells and cardiac
fibroblasts on cECM can be explored. Multiple cell types can be added together and the function
and survival rate of the CMs can be studied.
Addition of mechanical and electrical stimulation has been shown that can improve the
alignment and maturation of the differentiated CMs. For future studies, mechanical machines
that are able to stretch the cECM can be created and combined with electrical stimulators to
exercise and pace the cells. The use of mechanical and electrical stimulation can be studied in
order to obtain more mature cardiomyocytes. The alignment of CMs on the cECM can be studied
by fluorescently staining the cells and using confocal laser scanning microscopy. Also the
maturation level of the CMs can be studied by performing gene expression measurements of
relative genes such as cTNT, SCN5A, KIR2, RYR2, BNP and ANP.
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